


JC18 Rec'd PCT/PTO 0.4 MAR 2002

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER WALLACH=28
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/070255
INTERNATIONAL APPLICATION NO. PCT/IL00/00517	INTERNATIONAL FILING DATE 31 August 2000	PRIORITY CLAIMED 02 September 1999
TITLE OF INVENTION IREN PROTEIN, ITS PREPARATION AND USE		
APPLICANT(S) FOR DO/EO/US David WALLACH et al.		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Courtesy copy of the International Application as filed. <input checked="" type="checkbox"/> Courtesy copy of the first page of the International Publication (WO 01/16314). <input checked="" type="checkbox"/> Courtesy copy of the International Preliminary Examination Report. There were no annexes. <input checked="" type="checkbox"/> Formal drawings, 25 sheets, Figures 1-13B. <input checked="" type="checkbox"/> Courtesy Copy of the International Search Report. <input checked="" type="checkbox"/> Application Data Sheet <p><input checked="" type="checkbox"/> The application is (or will be) assigned to: Yeda Research and Development Co., Ltd., whose address is Weizmann Institute of Science, P.O. Box 95, 76100 Rehovot, Israel.</p>		

JC13 Rec'd PCT/PTO 0 4 MAR 2002

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NO.																																											
10/070255		PCT/IL00/00517		WALLACH=28																																											
<p>17. [xx] The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a)(1) –(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1040.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$890.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$740.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$710.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00</p> <p>ENTER APPROPRIATE BASIC FEE AMOUNT =</p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [X] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1"><thead><tr><th>Claims as Originally Presented</th><th>Number Filed</th><th>Number Extra</th><th>Rate</th></tr></thead><tbody><tr><td>Total Claims</td><td>50 - 20</td><td>30</td><td>X \$18.00</td></tr><tr><td>Independent Claims</td><td>6 - 3</td><td>3</td><td>X \$84.00</td></tr><tr><td colspan="3">Multiple Dependent Claims (if applicable)</td><td>+\$280.00</td></tr><tr><td colspan="3">TOTAL OF ABOVE CALCULATIONS =</td><td>\$2,092.00</td></tr></tbody></table> <table border="1"><thead><tr><th>Claims After Post Filing Prel. Amend</th><th>Number Filed</th><th>Number Extra</th><th>Rate</th></tr></thead><tbody><tr><td>Total Claims</td><td>- 20</td><td></td><td>X \$18.00</td></tr><tr><td>Independent Claims</td><td>- 3</td><td></td><td>X \$84.00</td></tr><tr><td colspan="3">TOTAL OF ABOVE CALCULATIONS =</td><td>\$2,092.00</td></tr></tbody></table> <p>Reduction of ½ for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.</p> <p>SUBTOTAL = \$2,092.00</p> <p>Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p> <p>TOTAL NATIONAL FEE = \$2,092.00</p> <p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</p> <p>TOTAL FEES ENCLOSED = \$2,092.00</p> <table border="1"><tr><td rowspan="2"></td><td>Amount to be:</td><td>\$</td></tr><tr><td>refunded</td><td></td></tr><tr><td></td><td>charged</td><td>\$</td></tr></table> <p>a. [] A check in the amount of \$_____ to cover the above fees is enclosed. b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$ 2,092.00, is attached. c. [] Please charge my Deposit Account No. 02-4035 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. d. [XX] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4035. A duplicate copy of this sheet is enclosed.</p> <p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO:</p> <p>BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, N.W., SUITE 300 WASHINGTON, D.C. 20001 TEL: (202) 628-5197 FAX: (202) 737-3528 Date of this submission: March 4, 2002</p> <div><p>SIGNATURE Jay M. Finkelstein NAME 21,082 REGISTRATION NUMBER</p></div>				Claims as Originally Presented	Number Filed	Number Extra	Rate	Total Claims	50 - 20	30	X \$18.00	Independent Claims	6 - 3	3	X \$84.00	Multiple Dependent Claims (if applicable)			+\$280.00	TOTAL OF ABOVE CALCULATIONS =			\$2,092.00	Claims After Post Filing Prel. Amend	Number Filed	Number Extra	Rate	Total Claims	- 20		X \$18.00	Independent Claims	- 3		X \$84.00	TOTAL OF ABOVE CALCULATIONS =			\$2,092.00		Amount to be:	\$	refunded			charged	\$
Claims as Originally Presented	Number Filed	Number Extra	Rate																																												
Total Claims	50 - 20	30	X \$18.00																																												
Independent Claims	6 - 3	3	X \$84.00																																												
Multiple Dependent Claims (if applicable)			+\$280.00																																												
TOTAL OF ABOVE CALCULATIONS =			\$2,092.00																																												
Claims After Post Filing Prel. Amend	Number Filed	Number Extra	Rate																																												
Total Claims	- 20		X \$18.00																																												
Independent Claims	- 3		X \$84.00																																												
TOTAL OF ABOVE CALCULATIONS =			\$2,092.00																																												
	Amount to be:	\$																																													
	refunded																																														
	charged	\$																																													

Rec'd Patent 20 AUG 2002

1007070255

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Box Sequence
David WALLACH et al.)	Examiner:
Appln. No.: 10/070,255)	Washington, D.C.
Filed: March 4, 2002)	August 20, 2002
For: IREN PROETIN, ITS)	Atty. Docket: WALLACH=28
PREPARATION AND USE...)	
Confirmation No.: 2930)	

RESPONSE TO NOTICE TO COMPLY WITH
SEQUENCE LISTING REQUIREMENTS

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply dated May 20, 2002, a petition for a one month extension of time being attached hereto, and prior to the examination of the above-described application, please amend the present application as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 20, line 8, with the following rewritten paragraph:

--Figures 13A-13H present the results of gene data bank analyses suggesting that genes closely related to IREN exist on several of the human chromosomes. The query (top strand) in the homology analyses with sequences in the gene data bank is always nucleotides 499-699 of SEQ ID NO:4. The

strand designated "sbjct" (bottom strand) in the different homology analyses are as follows:

Fig. 13A - nucleotides 499-699 of SEQ ID NO:4;

Fig. 13B - SEQ ID NO:10;

Fig. 13C - SEQ ID NO:10;

Fig. 13D - SEQ ID NO:10 and SEQ ID NO:11;

Fig. 13E - SEQ ID NO:12;

Fig. 13F - nucleotides 499-499 of SEQ ID NO:4 and SEQ ID NO:10;

Fig. 13G - SEQ ID NO:10;

Fig. 13H - SEQ ID NO:10--

Please replace the paragraph beginning at page 38, line 5, with the following rewritten paragraph:

--A non-limiting example of how peptide modulators of the IREN-TRAF2 interaction would be designed and screened is based on previous studies on peptide inhibitors of ICE or ICE-like proteases, the substrate specificity of ICE and strategies for epitope analysis using peptide synthesis. The minimum requirement for efficient cleavage of a peptide by ICE was found to involve four amino acids to the left of the cleavage site with a strong preference for aspartic acid in the P₁ position and with methylamine being sufficient to the right of the P₁ position (Sleath et al., 1990; Howard et al., 1991; Thronberry et al., 1992). Furthermore, the fluorogenic substrate peptide (a tetrapeptide), aceptyl-Asp-Glu-Val-Asp-a-(4-methyl-coumaryl-7-amide) (SEQ ID NO:13) abbreviated Ac-DEVD-

AMC, corresponds to a sequence in poly (ADP-ribose) polymerase (PARP) found to be cleaved in cells shortly after FAS-R stimulation, as well as other apoptotic processes (Kaufmann, 1989; Kaufmann et al., 1993; Lazebnik et al., 1994), and is cleaved effectively by CPP32 (a member of the CED3/ICE protease family) and MACH proteases.--

Please replace the paragraph beginning at page 39, line 1, with the following rewritten paragraph:

--Since it may be advantageous to design peptide inhibitors that selectively inhibit TRAF2-IREN (or TRAF-TRAF binding protein) interactions without interfering with physiological cell death processes in which other Members of the intracellular signaling pathway are involved, e.g. MACH proteases of the cell death pathway, which are members of the CED3/ICE family of proteases, the pool of peptides binding to TRAF2 (or TRAF) or IREN (or TRAF-binding proteins) in an assay such as the one described above can be further synthesized as a fluorogenic substrate peptide to test for selective binding to such other proteins to select only those specific for TRAF2/IREN (or TRAF/TRAF-binding protein). Peptides, which are determined to be specific for, for example, TRAF2/IREN, can then be modified to enhance cell permeability and inhibit the activity of TRAF2 and/or IREN either reversibly or irreversibly. Thornberry et al. (1994) reported that a tetrapeptide (acyloxy) methyl ketone Ac-Tyr-Val-Ala-Asp-CH₂OC(O)-[2,6-(CF₃)₂] Ph (SEQ ID NO:14) was a potent inactivator of ICE. Similarly, Milligan et al. (1995) reported that

In re Appln. No. 10/070,255

tetrapeptide inhibitors having a chloromethylketone (irreversibly) or aldehyde (reversibly) groups inhibited ICE. In addition, a benzyloxycarboxyl-Asp-CH₂OC (O) -2,6-dichlorobenzene (DCB) was shown to inhibit ICE (Mashima et al., 1995). Accordingly, in an analogous way, tetrapeptides that selectively bind to, for example, TRAF2 or IREN, can be modified with, for example, an aldehyde group, chloromethylketone, (acyloxy) methyl ketone or a CH₂OC (O)-DCB group to create a peptide inhibitor of TRAF2/IREN activity. Further, to improve permeability, peptides can be, for example, chemically modified or derivatized to enhance their permeability across the cell membrane and facilitate the transport of such peptides through the membrane and into the cytoplasm. Muranishi et al. (1991) reported derivatizing thyrotropin-releasing hormone with lauric acid to form a lipophilic lauroyl derivative with good penetration characteristics across cell membranes. Zacharia et al. (1991) also reported the oxidation of methionine to sulfoxide and the replacement of the peptide bond with its ketomethylene isoester (COCH₂) to facilitate transport of peptides through the cell membrane. These are just some of the known modifications and derivatives that are well within the skill of those in the art.--

IN THE SEQUENCE LISTING

Please substitute the attached Sequence Listing section for the originally filed sequence listing.

In re Appln. No. 10/070,255

IN THE DRAWINGS

Proposed corrected drawings of Figs. 13A and 13B with the proposed corrections marked in red are attached hereto for the examiner's approval.

In re Appln. No. 10/070,255

REMARKS

Proposed corrections to Figs. 13A and 13B to correct an error in the numbering of a nucleotide position in SEQ ID NO:4 and to present each sheet of Figs. 13A and 13B as a separate Figure, i.e., Figs. 13A-13H, are presented for the examiner's approval.

Applicants have added into the present specification a new paper copy Sequence Listing section according to 37 C.F.R. §1.821(c) as new pages. Furthermore, attached hereto is a 3 1/2" disk containing the "Sequence Listing" in computer readable form in accordance with 37 C.F.R. §1.821(e).

Applicants have amended the specification to insert SEQ ID Nos, as supported in the present specification.

The following statement is provided to meet the requirements of 37 C.F.R. §1.825(a) and 1.825(b).

I hereby state, in accordance with 37 C.F.R. §1.825(a), that the amendments included in the substitute sheets of the sequence listing are believed to be supported in the application as filed and that the substitute sheets of the sequence listing are not believed to include new matter.

I hereby further state, in accordance with 37 C.F.R. §1.825(b), that the attached copy of the computer readable form is the same as the attached substitute paper copy of the sequence listing.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment.

In re Appln. No. 10/070,255

The attached page is captioned "Version with markings to show changes made".


Applicants submit that the present application contains patentable subject matter and therefore urge the examiner to pass the case to issuance.

If the examiner has any questions or comments concerning the above described application, the examiner is urged to contact the undersigned at the phone number below.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By


Roger L. Browdy
Registration No. 25,618

RLB:pp
624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528

G:\BN\S\Ser1\Wallach28\pto\SEQRESPONSE TO NOTICE TO COMPLY.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

The paragraph beginning at page 20, line 8, has been rewritten as follows:

--Figures ~~13~~:13A-13H presents the results of gene data bank analyses suggesting that genes closely related to IREN exist on several of the human chromosomes. The query (top strand) in the homology analyses with sequences in the gene data bank is always nucleotides 499-699 of SEQ ID NO:4. The strand designated "sbjct" (bottom strand) in the different homology analyses are as follows:

Fig. 13A - nucleotides 499-699 of SEQ ID NO:4;

Fig. 13B - SEQ ID NO:10;

Fig. 13C - SEQ ID NO:10;

Fig. 13D - SEQ ID NO:10 and SEQ ID NO:11;

Fig. 13E - SEQ ID NO:12;

Fig. 13F - nucleotides 499-499 of SEQ ID NO:4 and SEQ ID NO:10;

Fig. 13G - SEQ ID NO:10;

Fig. 13H - SEQ ID NO:10--

The paragraph beginning at page 38, line 5, has been replaced with the following rewritten paragraph:

--A non-limiting example of how peptide modulators of the IREN-TRAF2 interaction would be designed and screened is based on previous studies on peptide inhibitors of ICE or ICE-like proteases, the substrate specificity of ICE and strategies

for epitope analysis using peptide synthesis. The minimum requirement for efficient cleavage of a peptide by ICE was found to involve four amino acids to the left of the cleavage site with a strong preference for aspartic acid in the P₁ position and with methylamine being sufficient to the right of the P₁ position (Sleath et al., 1990; Howard et al., 1991; Thronberry et al., 1992). Furthermore, the fluorogenic substrate peptide (a tetrapeptide), acetyl-Asp-Glu-Val-Asp-a-(4-methyl-coumaryl-7-amide) (SEQ ID NO:13) abbreviated Ac-DEVD-AMC, corresponds to a sequence in poly (ADP-ribose) polymerase (PARP) found to be cleaved in cells shortly after FAS-R stimulation, as well as other apoptotic processes (Kaufmann, 1989; Kaufmann et al., 1993; Lazebnik et al., 1994), and is cleaved effectively by CPP32 (a member of the CED3/ICE protease family) and MACH proteases.--

The paragraph beginning at page 39, line 1, has been rewritten as follows:

--Since it may be advantageous to design peptide inhibitors that selectively inhibit TRAF2-IREN (or TRAF-TRAF binding protein) interactions without interfering with physiological cell death processes in which other Members of the intracellular signaling pathway are involved, e.g. MACH proteases of the cell death pathway, which are members of the CED3/ICE family of proteases, the pool of peptides binding to TRAF2 (or TRAF) or IREN (or TRAF-binding proteins) in an assay such as the one described above can be further synthesized as a fluorogenic substrate peptide to test for selective binding

to such other proteins to select only those specific for TRAF2/IREN (or TRAF/TRAF-binding protein). Peptides, which are determined to be specific for, for example, TRAF2/IREN, can then be modified to enhance cell permeability and inhibit the activity of TRAF2 and/or IREN either reversibly or irreversibly. Thornberry et al. (1994) reported that a tetrapeptide (acyloxy) methyl ketone Ac-Tyr-Val-Ala-Asp-CH₂OC(O)-[2,6-(CF₃)₂] Ph (SEQ ID NO:14) was a potent inactivator of ICE. Similarly, Milligan et al. (1995) reported that tetrapeptide inhibitors having a chloromethylketone (irreversibly) or aldehyde (reversibly) groups inhibited ICE. In addition, a benzyloxycarboxyl-Asp-CH₂OC(O)-2,6-dichlorobenzene (DCB) was shown to inhibit ICE (Mashima et al., 1995). Accordingly, in an analogous way, tetrapeptides that selectively bind to, for example, TRAF2 or IREN, can be modified with, for example, an aldehyde group, chloromethylketone, (acyloxy) methyl ketone or a CH₂OC(O)-DCB group to create a peptide inhibitor of TRAF2/IREN activity. Further, to improve permeability, peptides can be, for example, chemically modified or derivatized to enhance their permeability across the cell membrane and facilitate the transport of such peptides through the membrane and into the cytoplasm. Muranishi et al. (1991) reported derivatizing thyrotropin-releasing hormone with lauric acid to form a lipophilic lauroyl derivative with good penetration characteristics across cell membranes. Zacharia et al. (1991) also reported the oxidation of methionine to sulfoxide and the replacement of the peptide bond with its ketomethylene

In re Appln. No. 10/070,255

isoester (COCH₂) to facilitate transport of peptides through the cell membrane. These are just some of the known modifications and derivatives that are well within the skill of those in the art.--

**COURTESY COPY OF THE
PCT APPLICATION AS
ORIGINALLY FILED WITH
SEQUENCE LISTING AND
ABSTRACT**

25 | p1/3

5

IREN PROTEIN, ITS PREPARATION AND USE

Field of the Invention

The present invention relates to DNA sequences encoding a TNF receptor associated factor (TRAF) binding protein. More specifically, it relates to cDNA
 10 sequences encoding a biologically active protein herein designated IREN and its isoforms capable of binding to TRAF2. The invention also relates to the proteins encoded by the above DNAs, and the use of said proteins and DNA sequences in the treatment or prevention of pathological conditions associated with NF- κ B induction, or with any other activity mediated by TRAF2, or with other molecules to which said
 15 protein binds.

Background of the Invention

The Tumor Necrosis Factor/Nerve Growth Factor (TNF/NGF) receptor superfamily represents a growing family with over 20 members identified so far in
 20 mammalian cells. Although the receptors of this superfamily differ in the primary sequence of their extracellular domains, the TNF/NGF receptor superfamily members share cysteine rich subdomains that are thought to adopt generally similar tertiary folds. (Bazan, 1993; Beutler and van Hufel, 1994; Smith et al., 1994). Except for two receptors, the p55 TNF receptor and Fas/APO1, the various members of this receptor
 25 family may have varying structural differences. Nevertheless, there is much similarity of function between the receptors, indicating that they share common signaling pathways. One example for this similarity is the ability of several receptors of the TNF/NGF family to activate the transcription factor NF- κ B (see hereinbelow).

TRAF2 is a member of a recently described family of proteins designated TRAF
 30 (TNF Receptor Associated Factor) that includes several proteins identified as, for example, TRAF1, TRAF2 (Rothe, M., et al (1994); PCT published application WO 95/33051), TRAF3 (Cheng, G. et al. (1995), TRAF4 (CART1, C-rich motif associated with RING and TRAF domains, Régnier et al. 1995), TRAF5 (Ishida et al. 1996a,

Nakano et al. 1996) and TRAF6 (see Cao et al. 1996a, Ishida et al. 1996b). All proteins belonging to the TRAF family share a high degree of amino acid identity in their C-terminal domains, while their N-terminal domains may be unrelated. As shown in a schematic illustration of TRAF2 (Fig. 1 herein), the molecule contains a ring finger motif and two TFIIIA-like zinc finger motifs at its N-terminal end. The C-terminal half of the molecule includes a region known as the "TRAF domain" containing a potential leucine zipper region extending between amino acids 264-358 (called N-TRAF). An additional domain towards the carboxy end of the molecule between amino acids 359-501 (called C-TRAF) is responsible for TRAF binding to the receptors and to other TRAF molecules to form homo- or heterodimers.

Recruitment of TRAF adapter proteins to the cytoplasmic domains of receptor molecules can lead to the assembly of larger signaling complexes that consist of distinct TRAF adapter molecules and other effector proteins with enzymatic functions. Numerous reports have examined the activation of intracellular kinases in response to TRAF-dependent signal transduction. In particular, kinases of the mitogen-activated protein kinase (MAPK) family have been shown to be key players for signaling pathways that are triggered by TRAF-containing complexes. These pathways appear to culminate in c-Jun amino-(N)-terminal kinase (JNK) activation (Reinhard et al. 1997; Song et al. 1997). TRAF proteins can thus serve to modulate the ability of receptors to trigger distinct signaling pathways that lead to phosphorylation and activation of protein kinases and, subsequently, to the activation of transcription factors of the Rel and AP-1 family.

The c-Jun transcription factor is phosphorylated at its amino terminus by JNK, the most downstream member of one MAPK signaling pathway (Hibi et al. 1993). To be activated JNK needs to be phosphorylated by a MAPK kinase (MAPKK, SEK, MEK). This kinase itself is phosphorylated by a MAPKKK (MEKK1), which can be activated through phosphorylation by GCKR (germinal center kinase related) protein, the most upstream kinase described in this pathway (Minden et al. 1994; Lin et al. 1995; Shi and Kehrl 1997). Dominant-negative mutants of either of these proteins that lack kinase activity block TRAF-mediated JNK activation that is induced by members of the TNF/NGFR superfamily. Thus, TRAF proteins appear to regulate the JNK activation pathway at a very proximal step (Liu et al. 1996; Lee et al. 1997; Reinhard et al. 1997). Cells from TRAF2-deficient mice failed to activate JNK in response to TNF α (Yeh et

al. 1997). JNK has been demonstrated to mediate the integration of a co-stimulatory signal by CD28 during activation of T lymphocytes (Su et al. 1994). Taken together, these results suggest that co-stimulation by CD28 and TRAF-mediated co-stimulation, after ligation of TNFR-related molecules, utilize the same distal signaling components.

5 TRAF proteins also appear to play an important role in modulating an early step in receptor-induced activation of NF- κ B (Rothe et al. 1995b; Cao et al. 1996; Nakano et al. 1996). NF- κ B comprises members of a family of dimer-forming proteins with homology to the Rel oncogene which, in their dimeric form, act as transcription factors. These factors are ubiquitous and participate in regulation of the expression of multiple
10 genes. Although initially identified as a factor that is constitutively present in B cells at the stage of Ig κ light chain expression, NF- κ B is known primarily for its action as an inducible transcriptional activator. In most known cases NF- κ B behaves as a primary factor, namely the induction of its activity is by activation of pre-existing molecules present in the cell in their inactive form, rather than its de-novo synthesis which in turn
15 relies on inducible transcription factors that turn-on the NF- κ B gene. The effects of NF- κ B are highly pleiotropic. Most of these numerous effects share the common features of being quickly induced in response to an extracellular stimulus. The majority of the NF- κ B-activating agents are inducers of immune defense, including components of viruses and bacteria, cytokines that regulate immune response, UV light and others.
20 Accordingly, many of the genes regulated by NF- κ B contribute to immune defense (see Blank et al., 1992; Grilli et al., 1993; Baeuerle and Henkel, 1994, for reviews).

One major feature of NF- κ B-regulation is that this factor can be found in a cytoplasmic non-DNA binding form which can be induced to translocate to the nucleus, bind DNA and activate transcription. This dual form of the NF- κ B proteins is regulated
25 by I- κ B - a family of proteins that contain repeats of a domain that was initially identified in the erythrocyte protein ankyrin (Gilmore and Morin, 1993). In the unstimulated form, the NF- κ B dimer occurs in association with an I- κ B molecule which imposes its cytoplasmic localization preventing its interaction with the NF- κ B-binding DNA sequence, and activation of transcription. The dissociation of I- κ B from the
30 NF- κ B dimer constitutes its critical activation step by many of its inducing agents (DiDonato et al., 1995). There is so far little understanding of the way in which cell

specificity is determined in terms of responsiveness to the various NF- κ B-inducing agents.

Evidence that TRAF proteins can influence receptor-mediated activation of NF- κ B came from the demonstration that dominant-negative forms of TRAF2 can
 5 inhibit NF- κ B activation in response to oligomerization of several TNFR-related molecules, including TNFRII, CD40, CD30, 4-1BB, and Ox40 (Rothe et al. 1994, 1995b; Duckett et al. 1997; Arch and Thompson 1998). However, gene elimination studies in mice have failed to implicate a required role for a specific TRAF in NF- κ B activation by any of these receptors (Lee et al. 1997; Yeh et al. 1997). This suggests that
 10 receptor engagement may activate NF- κ B by more than one pathway.

One of the most potent inducing agents of NF- κ B is the cytokine tumor necrosis factor (TNF). There are two different TNF receptors: the p55 and p75 receptors. Their expression levels vary independently among different cells (Vandenabeele et al., 1995). The p75 receptor responds preferentially to the cell-bound form of TNF (TNF is
 15 expressed both as a type II-transmembrane protein and as a soluble protein) while the p55 receptor responds just as effectively to soluble TNF molecules (Grell et al., 1995). The intracellular domains of the two receptors are structurally unrelated and bind different cytoplasmic proteins. Nevertheless, at least part of the effects of TNF, including the cytotoxic effect of TNF and the induction of NF- κ B, can be induced by
 20 both receptors. This feature is cell specific. The p55 receptor is capable of inducing a cytotoxic effect or activation of NF- κ B in all cells that exhibit such effects in response to TNF. The p75-R can have such effects only in some cells. Others, although expressing the p75-R at high levels, show induction of the effects only in response to stimulation of the p55-R (Vandenabeele et al., 1995). Apart from the TNF receptors,
 25 various other receptors of the TNF/NGF receptor family: CD30 (McDonald et al., 1995), CD40 (Berberich et al., 1994; Lalmanach-Girard et al., 1993), the lymphotoxin beta receptor and, in a few types of cells, Fas/APO1 (Rensing-Ehl et al., 1995) are also capable of inducing activation of NF- κ B. The IL-1 type-I receptor, also effectively triggering NF- κ B activation, shares most of the effects of the TNF receptors despite the
 30 fact that it has no structural similarity to them. Novel receptor subunits of the IL-18 receptor complex have been recently cloned and shown to trigger NF- κ B translocation and activation in response to IL-18 (Born et al. 1998). The IL-1Rrp as well as a novel

[illegible]

The activation of NF- κ B upon triggering of these various receptors results from induced phosphorylation of its associated I- κ B molecules. Several components of a specific signal transduction cascade, activated in response to the proinflammatory cytokines TNF- α or IL-1 β , have recently been identified. A novel protein kinase designated NIK for NF- κ B Inducing Kinase was the first to be identified (see co-pending co-owned Patent Application WO 97/37016, Malinin et al. 1996). NIK was found to bind to TRAF2 and to stimulate NF- κ B activation. NIK shares sequence similarity with MAP3K kinases and participates in the NF- κ B inducing signaling cascade common to receptors of the TNF/NGF family and to the IL-1 type 1 receptor. TNF- α and IL-1 β , initiate a signaling cascade leading to activation of two I κ B kinases, IKK-1 [IKK- α] and IKK-2 [IKK- β], which phosphorylate I κ B at specific N-terminal serine residues [S32 and S36 for I κ B α S19 and S23 for I κ B β] (for review see Mercurio F and Manning AM, 1999). These kinases were identified as the components of a high molecular weight protein complex designated the IKK signalsome.

Phosphorylated I κ B is selectively ubiquitinated by an E3 ubiquitin ligase, the terminal member of a cascade of ubiquitin conjugating enzymes. In the last step of this signaling cascade, phosphorylated and ubiquitinated I κ B, which is still associated with NF- κ B in the cytoplasm, is selectively degraded by the 26S proteasome. This process exposes the NLS, therefore freeing NF- κ B to interact with the nuclear import machinery and translocate to the nucleus, where it binds its target genes to initiate transcription.

The identification of several additional components of the IKK signalsome has given a clue to the potential mechanisms by which receptor activation might be linked to IKK activation. One of these is an NF- κ B essential modulator designated NEMO. This murine protein was found to be essential for the activation of NF- κ B in a flat cellular variant of HTLV-1 Tax transformed fibroblasts which is unresponsive to all tested NF- κ B stimuli (Yamaoka et al. 1998). NEMO was shown to homodimerize and to directly interact with IKK2. The same protein was independently cloned by Kovalenko et al. (see co-pending co-owned Israel Patent Application Nos. 123758 and 126024) as a RIP-binding protein and designated RAP-2. NEMO was later independently cloned by

two other groups as a non-kinase component of the IKK signalsome and designated IKKAP-1 (Mercurio F et al 1999b, Rothwarf DM et al 1998). The same protein was also cloned as an E3 interacting protein, which is an adenoviral protein, encoded by the early transcription region and functions to inhibit the cytolytic effects of TNF and was shown to interact with RIP kinase (Li Y et al 1998). These studies provide evidence that NEMO mediates an essential step of the NF- κ B signal transduction pathway. Three receptor-associated proteins appear to take part in initiation of the phosphorylation cascade (see diagrammatic illustration in Fig. 2). TRAF2, which when expressed at high levels can by itself trigger NF- κ B activation, binds to activated p75 TNF-R (Rothe et al., 1994), lymphotoxin beta receptor (Mosialos et al., 1995), CD40 (Rothe et al., 1995a) and CD-30 (unpublished data) and mediates the induction of NF- κ B by them. TRAF2 does not bind to the p55 TNF receptor nor to Fas/APO1, however, it can bind to the p55 receptor-associated protein called TRADD and TRADD has the ability to bind to a Fas/APO1-associated protein called MORT1 (or FADD - see Boldin et al. 1995b and 1996). Another death domain containing serine/threonine kinase receptor-interacting protein, designated RIP (see Stanger et al., 1995) is also capable of interacting with TRAF2 as well as with FAS/APO1, TRADD, the p55 TNF receptor and MORT-1. Thus, while RIP was initially associated with cell cytotoxicity induction (cell death), its ability to interact with TRAF2 also implicates it in NF- κ B activation.

TRAF molecules appear to be involved in the pathway leading to NF- κ B activation. These associations apparently allow the p55 TNF receptor and Fas/APO1 to trigger NF- κ B activation (Hsu et al., 1995; Boldin et al., 1995; Chinnaiyan et al., 1995; Varfolomeev et al., 1996; Hsu et al., 1996). The triggering of NF- κ B activation by the IL-1 receptor occurs independently of TRAF2 and may involve a TRAF2 homologue – TRAF6 and a recently-cloned IL-1 receptor-associated protein-kinase called IRAK (Croston et al., 1995). TRAF6 and IRAK have been also shown to play an important role in IL-18-induced signaling and function (Kanarakaraj et al.1999).

The signaling cascades that are initiated by receptor recruitment of either TRAF molecules or death domain containing adapter proteins are regulated by proteins that can interfere with specific steps by modifying the composition of the multiprotein complexes and/or by blocking protein-protein interactions and downstream effector functions. Several cytoplasmic molecules that bind to TRAFs have been identified.

Among them A20, c-IAPs (cellular Inhibitors of Apoptosis), TRIP (TRAF interacting protein) and I-TRAF/TANK (TRAF interacting protein, TRAF family members-associated NF- κ B activator). (Rothe et al., 1994; Rothe et al., 1995b; Cheng and Baltimore 1996; Lee et al. 1997; Roy et al. 1997) and two others, one of which is designated clone 9, which shows some sequence homology to the proteins of the present invention, and another designated clone 15 (see co-pending co-owned Patent Application WO 97/37016). Each of these proteins has been shown to be capable at least of binding, and some also of interacting with members of the TRAF family. Yet, the functional roles of these interactions have been demonstrated to be quite distinct. These proteins may be an important link in the ability of TRAF-dependent signal transduction to modulate cell survival. In fact it is not yet clear how TRAFs, trigger the phosphorylation of I- κ B. There is also no information yet as to the mechanisms that dictate cell-specific pattern of activation of TRAFs by different receptors, such as observed for the induction of NF- κ B by the two TNF receptors. The crystal structure of the TRAF domain of human TRAF has been recently solved (Park, Y.C. et al. 1999). The structure reveals a trimeric self-association of the TRAF domain, which provides an avidity-based explanation for the dependence of TRAF recruitment on the oligomerization of the receptors by their trimeric extracellular ligands.

Accordingly, as regards NF- κ B activation and its importance in maintaining cell viability, the various intracellular pathways involved in this activation have heretofore not been clearly elucidated, for example, how the various TRAF proteins, are involved directly or indirectly.

Furthermore, as is now known regarding various members of the TNF/NGF receptor family and their associated intracellular signaling pathways inclusive of various adapter, mediator/modulator proteins (see brief reviews and references in, for example, co-pending co-owned Israel Patent Application Nos. 114615, 114986, 115319, 116588), TNF and the FAS/APO1 ligand, for example, can have both beneficial and deleterious effects on cells. TNF, for example, contributes to the defense of the organism against tumors and infectious agents and contributes to recovery from injury by inducing the killing of tumor cells and virus-infected cells, augmenting antibacterial activities of granulocytes, and thus in these cases the TNF-induced cell killing is desirable. However, excess TNF can be deleterious and as such TNF is known to play a major pathogenic

role in a number of diseases such as septic shock, anorexia, rheumatic diseases, inflammation and graft-vs-host reactions. In such cases TNF-induced cell killing is not desirable. The FAS/APO1 ligand, for example, also has desirable and deleterious effects. This FAS/APO1 ligand induces via its receptor the killing of autoreactive T cells during maturation of T cells, i.e. the killing of T cells which recognize self-antigens, during their development and thereby preventing autoimmune diseases. Further, various malignant cells and HIV-infected cells carry the FAS/APO1 receptor on their surface and can thus be destroyed by activation of this receptor by its ligand or by antibodies specific thereto, and thereby activation of cell death (apoptosis) intracellular pathways mediated by this receptor. However, the FAS/APO1 receptor may mediate deleterious effects, for example, uncontrolled killing of tissue which is observed in certain diseases such as acute hepatitis that is accompanied by the destruction of liver cells.

In view of the above, i.e. that receptors of the TNF/NGF family can induce cell death pathways on the one hand and can induce cell survival pathways (via NF- κ B induction) on the other hand, there apparently exists a fine balance, intracellularly between these two opposing pathways. For example, when it is desired to achieve maximal destruction of cancer cells or other infected or diseased cells, it would be desired to have TNF and/or the FAS/APO1 ligand inducing only the cell death pathway without inducing NF- κ B. Conversely, when it is desired to protect cells such as in, for example, inflammation, graft-vs-host reactions, acute hepatitis, it would be desirable to block the cell killing induction of TNF and/or FAS/APO1 ligand and enhance, instead, their induction of NF- κ B. Likewise, in certain pathological circumstances it would be desirable to block the intracellular signaling pathways mediated by the p75 TNF receptor and the IL-1 receptor, while in others it would be desirable to enhance these intracellular pathways.

Summary of the Invention

It is an object of the present invention to provide a biologically active protein, isoforms, analogs, fragments or derivatives thereof capable of binding to the tumor necrosis factor receptor-associated factor (TRAF) proteins. As the TRAF binding proteins are involved in the modulation or mediation of the activation of the

The biologically active protein of the invention and its isoforms, analogs, fragments or derivatives may likewise be indirect modulators/mediators of the intracellular biological activity of a variety of other proteins which are capable of interacting with TRAF proteins directly or indirectly (e.g. FAS/APO1 receptor, p55 TNF receptor, p75 TNF receptor, IL-1 receptor and their associated proteins, such as, for example, MORT-1, TRADD, RIP).

Another object of the invention is to provide antagonists (e.g. antibodies, peptides, organic compounds, or even some isoforms) to the above novel TRAF-binding protein, isoforms, analogs, fragments and derivatives thereof, which may be used to inhibit the signaling process, or, more specifically, to inhibit the activation of NF- κ B and its associated involvement in cell-survival processes, when desired. Likewise, when the TRAF-binding protein of the invention or the TRAF protein to which they bind (e.g. TRAF3) are themselves inhibitory for NF- κ B activation (either directly, or through modulation of the trafficking or stability of the proteins to which they bind), then it is an object to provide antagonists to the TRAF-binding protein to activate the signaling process or more specifically, to block the inhibition of NF- κ B activation and hence bring about enhanced NF- κ B activation, when desired.

A further object of the invention is to use the above novel TRAF-binding protein, isoforms, analogs, fragments and derivatives thereof, to isolate and characterize additional proteins or factors, which may be involved in regulation of TRAF protein activity and/or the above noted receptor activity, e.g. other proteins which may bind to TRAF proteins and influence their activity, and/or to isolate and identify other receptors or other cellular proteins further upstream or downstream in the signaling process(es) to

More specifically, the present invention provides a DNA sequence encoding a protein capable of binding to TRAF selected from:

(a) a cDNA sequence of the herein designated IREN comprising the nucleotide sequence depicted in Fig. 3;

5 (b) a cDNA sequence of the herein designated isoform IREN-10B comprising the nucleotide sequence depicted in Fig. 4;

(c) a cDNA sequence of the herein designated isoform IREN-E comprising the nucleotide sequence depicted in Fig. 5;

(d) a fragment of a sequence (a)-(c) which encodes a biologically active protein capable of binding to at least the residues 225-501 of the amino acid sequence of TRAF2;

(e) A DNA sequence capable of hybridization to a sequence of (a)-(d) under moderately stringent conditions and which encodes a biologically active protein capable of binding to at least the residues 225-501 of the amino acid sequence of TRAF2; and

15 (f) A DNA sequence, which is degenerate as a result of the genetic code to the DNA sequences, defined in (a)-(e) and which encodes a biologically active protein capable of binding to at least the residues 225-501 of the amino acid sequence of TRAF2.

20 Embodiments of the above DNA sequence of the invention encoding the protein encoded by IREN include:

(i) A DNA sequence encoding the protein IREN, its biologically active isoforms, fragments or analogs thereof, capable of binding to TRAF2 and capable of modulating the activity of NF- κ B and IREN isoforms, fragments or analogs thereof;

25 (ii) A DNA sequence as in (i) above, selected from the group consisting of:

a) A cDNA sequence derived from the coding region of a native IREN protein;

b) DNA sequences capable of hybridization to a sequence of (a) under moderately stringent conditions and which encode a biologically active IREN; and

30

c) DNA sequences, which are degenerate as a result of the genetic code to the sequences, defined in (a) and (b) and which encode a biologically active IREN protein;

(iii) A DNA sequence as in (i) or (ii) above comprising at least part of the sequence depicted in Fig. 3 and encoding at least one active IREN protein, isoform, analog or fragment;

(iv) A DNA sequence as in (iii) above encoding an IREN protein, isoform, analog, or fragment having at least part of the amino acid sequence depicted in Fig. 3.

In another aspect, the invention provides proteins or polypeptides encoded by the above noted DNA, provided that they are capable of binding to TRAF2, preferably to at least the 225-501 amino acid sequence of TRAF2 and the isoforms, analogs, fragments and derivatives of said protein and polypeptides. Embodiments of these proteins/polypeptides, according to the invention include:

- (a) A protein being the protein herein designated IREN;
- (b) Isoforms, fragments, analogs and derivatives thereof; and
- (c) An IREN protein, isoforms, analogs, fragments and derivatives thereof having at least part of the amino acid sequence depicted in Fig. 6.

In yet another aspect, the invention provides a vector comprising any of the above DNA sequences according to the invention which are capable of being expressed in host cells selected from prokaryotic and eukaryotic cells; as well as transformed prokaryotic and eukaryotic cells containing said vector.

The invention also provides a method for producing a protein, isoform, analog, fragment or derivative encoded by any of the above DNA sequences according to the invention which comprises growing the above mentioned transformed host cells under conditions suitable for the expression of said protein, isoforms, analogs, fragments or derivatives, effecting post-translational modification, as necessary, for obtaining said protein, isoform, analogs, fragments or derivatives and isolating said expressed protein, isoforms, analogs, fragments or derivatives.

In a further aspect, the invention provides antibodies or active fragments or derivatives thereof, specific for the above TRAF-binding proteins, analogs, isoforms, fragments or derivatives thereof or specific for the IREN protein, isoform, analog, fragment or derivative thereof noted above.

In a different aspect, the invention provides the following screening methods:

- (i) A method for screening of a ligand capable of binding to a protein according to the invention, as noted above, including isoforms, analogs, fragments or derivatives thereof, comprising contacting an affinity chromatography matrix to which said protein, isoform, analog, fragment or derivative is attached with a cell extract whereby the ligand is bound to said matrix, and eluting, isolating and analyzing said ligand.
- (ii) A method for screening of a DNA sequence coding for a ligand capable of binding to a protein, isoform, analog, fragment or derivative according to the invention as noted above, comprising applying the yeast two-hybrid procedure in which a sequence encoding said protein, isoform analog, derivative or fragment is carried by one hybrid vector and sequences from a cDNA or genomic DNA library are carried by the second hybrid vector, transforming yeast host cells with said vectors, isolating the positively transformed cells, and extracting said second hybrid vector to obtain a sequence encoding said ligand.

Similarly, there is also provided a method for isolating and identifying proteins, isoforms, analogs, fragments according to the invention noted above, capable of binding directly to TRAF2, comprising applying the yeast two-hybrid procedure in which a sequence encoding said TRAF2 is carried by one hybrid vector and sequence from a cDNA or genomic DNA library is carried by the second hybrid vector, the vectors then being used to transform yeast host cells and the positive transformed cells being isolated, followed by extraction of the said second hybrid vector to obtain a sequence encoding a protein which binds to said TRAF2.

In yet another aspect of the invention there is provided a method for the modulation or mediation in cells of the activity of NF- κ B or any other intracellular signaling activity modulated or mediated by TRAF2 or by other molecules to which a protein, isoform, analog, fragment or derivative thereof of the invention as noted above, said method comprising treating said cells by introducing into said cells one or more of said protein, isoform, analog, fragment or derivative thereof in a form suitable for intracellular introduction thereof, or introducing into said cells a DNA sequence encoding said one or more protein, isoform, analog, fragment or derivative thereof in the form of a suitable vector carrying said sequence, said vector being capable of effecting

the insertion of said sequence into said cells in a way that said sequence is expressed in said cells.

Embodiments of this above method for modulation/mediation in cells of the activity of NF- κ B or any other intracellular signaling activity modulated or mediated by TRAF2 or other molecules include:

(i) A method as above, wherein said treating of cells comprises introducing into said cells a DNA sequence encoding said IREN protein, isoform, fragment, analog or derivative in the form of a suitable vector carrying said sequence, said vector being capable of effecting the insertion of said sequence into said cells in a way that said sequence is expressed in said cells.

(ii) A method as above wherein said treating of said cells is by transfection of said cells with a recombinant animal virus vector comprising the steps of:

(a) constructing a recombinant animal virus vector carrying a sequence encoding a viral surface protein (ligand) that is capable of binding to a specific cell surface receptor on the surface of said cells to be treated and a second sequence encoding said IREN protein isoforms, analogs, fragments and derivatives according to the invention, that when expressed in said cells is capable of modulating/mediating the activity of NF- κ B or any other intracellular signaling activity modulated/mediated by TRAF2 or other said molecules; and

(b) infecting said cells with said vector of (a).

Likewise, the present invention also provides a method for modulating TRAF2 modulated/mediated effect on cells comprising treating said cells with the antibodies or active fragments or derivatives thereof, according to the invention as noted above, said treating being by application of a suitable composition containing said antibodies, active fragments or derivatives thereof to said cells, wherein when the IREN protein or portions thereof of said cells are exposed on the extracellular surface, said composition is formulated for extracellular application, and when said IREN protein is intracellular said composition is formulated for intracellular application.

Other methods of the invention for modulating the TRAF2 modulated/mediated effect on cells include:

(i) A method comprising treating said cells with an oligonucleotide sequence encoding an antisense sequence for at least part of the DNA sequence encoding said

(ii) A method as in (i) above wherein said oligonucleotide sequence is
5 introduced to said cells via a recombinant virus as noted above, wherein said second
sequence of said virus encodes said oligonucleotide sequence.

(iii) A method comprising applying the ribozyme procedure in which a vector encoding a ribozyme sequence capable of interacting with a cellular mRNA sequence encoding said IREN protein, isoform, analog, fragment or derivative of the invention noted above, is introduced into said cells in a form that permits expression of said ribozyme sequence in said cells, and wherein when said ribozyme sequence is expressed in said cells it interacts with said cellular mRNA sequence and cleaves said mRNA sequence resulting in the inhibition of expression of said IREN protein in said cells.

In the above methods and embodiments thereof of the invention there is included also a method for the prevention or treatment of a pathological condition associated with NF- κ B induction or with any other activity mediated by TRAF2 or by other molecules to which a protein, isoform, analog, fragment or derivative, according to the invention, binds, said method comprising administering to a patient in need an effective amount of a protein, isoform, analog, fragment or derivative, according to the invention, or a DNA molecule coding therefor, or a molecule capable of disrupting the interaction of said protein, isoform, analog, fragment or derivative, with TRAF2 or any other molecule to which said protein, isoform, analog, fragment or derivative binds. In this method of the invention, said protein of the invention administered to the patient in need can be specifically the protein encoded by IREN, or a DNA molecule coding therefor. The protein encoded by IREN is believed at present to modulate NF- κ B induction by IKK-1 and NIK. In an additional aspect of the invention there is provided a pharmaceutical composition for the modulation of the TRAF2 modulated/mediated effect on cells comprising, as active ingredient IREN its biologically active fragments, analogs, derivatives or mixtures thereof.

30 Other pharmaceutical compositions or embodiments thereof according to the invention include:

(i) A pharmaceutical composition for modulating the TRAF2 modulated/mediated effect on cells comprising, as active ingredient, a recombinant animal virus vector encoding a protein capable of binding a cell surface receptor and IREN, its biologically active isoforms, active fragments or analogs, according to the invention.

(ii) A pharmaceutical composition for modulating the TRAF2 modulated/mediated effect on cells comprising as active ingredient, an oligonucleotide sequence encoding an anti-sense sequence of the IREN mRNA sequence according to the invention.

In yet another specific embodiment, the invention provides a pharmaceutical composition for the prevention or treatment of a pathological condition associated with NF- κ B induction or with any other activity mediated by TRAF2 or by other molecules to which the protein IREN binds, said composition comprising a molecule capable of interfering with the activity of IREN. In this composition, the interfering molecule may be an effective amount of IREN mutated in active site residues, this mutated IREN serving to interfere with native IREN.

One known condition associated with NF- κ B induction (abnormal) is AIDS, others are e.g. autoimmune diseases, as well as tumors.

Still further aspects and embodiments of the invention are:

It should be noted that, where used throughout, the following terms:
 “modulation/mediation of the TRAF (or TRAF2) effect on cells” and any other such
 “modulation/mediation” mentioned in the specification are understood to encompass *in*
vitro as well as *in vivo* treatment and, in addition, also to encompass inhibition or
 5 enhancement/augmentation.

Description of Figures

Figure 1: shows a diagrammatic illustration of the structure of the TRAF2 molecule.

10 **Figure 2:** shows a schematic diagram illustrating some of the proteins involved in NF- κ B activation.

Figure 3A shows the nucleotide sequence of IREN’s 5-prime UTR (from the beginning of the sequence until ATG with Kozak sequence) which is identical in all 3 IREN splice isoforms (SEQ ID NO:3).

15 **Figure 3B:** shows the nucleotide sequence of IREN (SEQ ID NO:4).

Figure 4: shows the nucleotide sequence of IREN-10B (SEQ ID NO:5).

Figure 5: shows the nucleotide sequence of IREN-E (SEQ ID NO:6).

Figure 6: shows the amino acid sequence of IREN (SEQ ID NO:7).

Figure 7: shows the amino acid sequence of IREN-10B (SEQ ID NO:8).

20 **Figure 8:** shows the amino acid sequence of IREN-E (SEQ ID NO:9).

Figure 9: shows a comparison between the sequence of IREN and its isoforms IREN-10B and IREN-E.

Figure 10: shows in a diagrammatic fashion results of induction of NF- κ B activation by IKK-1, by wild type IREN, NIK and NEMO and mutants thereof.

25 **Figure 11:** shows an autoradiogram of FLAG-IKK1, GST-I κ B and NEMO, obtained after transfection of 293 cells with pcFLAG CHUK (encoding murine IKK1) and pc20.4 (encoding the NEMO protein), together with pcHIS-IREN Δ N (pcHIS-IREN₁₉₈₋₅₄₁, left lane), pcHIS-IREN (middle lane), or the empty pcDNA3 vector (right lane) as control. Immunoprecipitation and kinase assays were carried out as described in

Example 3. The sizes of the visible bands correspond to the molecular weights determined for FLAG-IKK1, GST-IkappaB and NEMO.

Figure 12 : shows an autoradiogram (left) and immunostaining (right) of SDS-PAGE analysis of IREN 10B and IREN that were immunoprecipitated from transfected cells and then subjected to an in vitro kinase test. The figure demonstrates that IREN 10B associates in cells with a protein kinase that can phosphorylate this IREN splice variant.

Figure 13 : presents the results of gene data bank analyses suggesting that genes closely related to IREN exist on several of the human chromosomes.

10

Detailed Description of the Invention

The present invention concerns a cDNA sequence herein designated IREN, (depicted in Fig. 3), which encodes for a protein capable of binding to TRAF2, and the proteins encoded by this DNA sequences. The invention also concerns cDNA sequences of IREN isoforms IREN-10B and IREN-E (depicted in Figs. 4 and 5, respectively).

The DNA and the deduced amino acid sequences mentioned above do not appear in the 'GENEBANK' or 'PROTEIN BANK' data banks of DNA or amino acid sequences, they thus represent hitherto unknown sequences.

Within the scope of the present invention are also fragments of the above mentioned DNA sequences and DNA sequences capable of hybridization to those sequences or part of them, under moderately stringent conditions, provided they encode a biologically active protein or polypeptide capable of binding to at least the 225-501 amino acid sequence of TRAF2.

The present invention also concerns a DNA sequence which is degenerate as a result of the genetic code to the above mentioned DNA sequences and which encodes a biologically active protein or polypeptide capable of binding to at least the 225-501 amino acid sequence of TRAF2.

As regards TRAF2, it should be noted that several members of the TNF/NGF receptor family activate the transcription factor NF- κ B by direct or indirect association with TRAF2, which is thus an adapter protein for these receptors and may thus also be considered as a modulator/mediator of the induction of NF- κ B activation activity of

these TNF/NGF receptors (see the scheme in Fig.2). Another receptor, the IL-1 receptor activates NF- κ B independently of TRAF2. IREN analogs or muteins produced in accordance with the present invention (see Examples) otherwise modulate NF- κ B activation, when these analogs/muteins are expressed in cells.

5 Thus, the present invention concerns the IREN protein, as well as the biologically active isoforms, analogs, fragments and derivatives thereof, and the isoforms, analogs, fragments and derivatives of the proteins encoded thereby. The preparation of such analogs, fragments and derivatives is by standard procedures (see for example, Sambrook et al., 1989) in which in the DNA encoding sequences, one or
10 more codons may be deleted, added or substituted by another, to yield encoded analogs having at least a one amino acid residue change with respect to the native protein. Acceptable analogs are those which retain at least the capability of binding to TRAF2 with or without mediating any other binding or enzymatic activity, e.g. analogs which bind TRAF2 but do not signal, i.e. do not bind to a further downstream protein or other
15 factor, or do not catalyze a signal-dependent reaction. In such a way analogs can be produced which have a so-called dominant-negative effect, namely, an analog, which is defective either in binding to TRAF2 or in subsequent signaling following such binding as, noted above. Such analogs can be used, for example, to inhibit the CD40, p55 TNF and p75 TNF (FAS/APO1 and other related receptor effects, as well as effected
20 mediated by various receptor associated proteins (adapters) as noted above, by competing with the natural IREN proteins. Likewise, so-called dominant-positive analogs may be produced which would serve to enhance the TRAF2 effect. These would have the same or better TRAF2-binding properties and the same or better signaling properties than natural TRAF2-binding proteins. In an analogous fashion, biologically
25 active fragments of the clones of the invention may be prepared as noted above with respect to the preparation of the analogs. Suitable fragments of the DNA sequences of the invention are those that encode a protein or polypeptide retaining the TRAF2 binding capability or which can mediate any other binding or enzymatic activity as noted above. Accordingly, fragments of the encoded proteins of the invention can be
30 prepared which have a dominant-negative or a dominant-positive effect as noted above with respect to the analogs. Similarly, derivatives may be prepared by standard modifications of the side groups of one or more amino acid residues of the proteins,

their analogs or fragments, or by conjugation of the proteins, their analogs or fragments, to another molecule e.g. an antibody, enzyme, receptor, etc., as are well known in the art.

Of the above DNA sequences of the invention which encode the TRAF2-binding protein IREN, biologically active isoforms, analogs, fragments or derivatives, there is also included, as an embodiment of the invention, DNA sequences capable of hybridizing with a cDNA sequence derived from the coding region of a native TRAF-binding protein, in which such hybridization is performed under moderately stringent conditions, and which hybridizable DNA sequences encode a biologically active TRAF-binding protein. These hybridizable DNA sequences therefore include DNA sequences which have a relatively high homology to the native IREN cDNA sequence and as such represent TRAF-binding protein-like sequences which may be, for example, naturally-derived sequences encoding the various IREN isoforms, or naturally-occurring sequences encoding proteins belonging to a group of TRAF-binding protein-like sequences encoding IREN. Further, these sequences may also, for example, include non-naturally occurring, synthetically produced sequences, that are similar to the native IREN cDNA sequence but incorporate a number of desired modifications. Such synthetic sequences therefore include all of the possible sequences encoding analogs, fragments and derivatives of IREN, all of which have the activity of TRAF-binding proteins.

As used herein, stringency conditions are a function of the temperature used in the hybridization experiment, the molarity of the monovalent cations and the percentage of formamide in the hybridization solution. To determine the degree of stringency involved with any given set of conditions, one first uses the equation of Meinkoth et al. (1984) for determining the stability of hybrids of 100% identity expressed as melting temperature T_m of the DNA-DNA hybrid:

$$T_m = 81.5^{\circ} \text{C} + 16.6 (\text{LogM}) + 0.41 (\% \text{GC}) - 0.61 (\% \text{ form}) - 500/L$$

where M is the molarity of monovalent cations, %GC is the percentage of G and C nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. For each 1°C that the T_m is reduced from that calculated for a 100% identity hybrid, the amount of mismatch permitted is increased by about 1%. Thus, if the T_m used for any given hybridization experiment at the specified salt and formamide concentrations is 10°C below the T_m

calculated for a 100% hybrid according to the equation of Meinkoth, hybridization will occur even if there is up to about 10% mismatch.

Thus "highly stringent conditions" are those which provide a T_m which is not more than 10^0 C below the T_m that would exist for a perfect duplex with the target sequence, either as calculated by the above formula or as actually measured. "Moderately stringent conditions" are those which provide a T_m which is not more than 20^0 C below the T_m that would exist for a perfect duplex with the target sequence, either as calculated by the above formula or as actually measured. Without limitation, examples of highly stringent (5- 10^0 C below the calculated or measured T_m of the hybrid) and moderately stringent (15- 20^0 C below the calculated or measured T_m of the hybrid) conditions use a wash solution of 2 X SSC (standard saline citrate) and 0.5% SDS (sodium dodecyl sulfate) at the appropriate temperature below the calculated T_m of the hybrid. The ultimate stringency of the conditions is primarily due to the washing conditions, particularly if the hybridization conditions used are those which allow less stable hybrids to form along with stable hybrids. The wash conditions at higher stringency then remove the less stable hybrids. A common hybridization condition that can be used with the highly stringent to moderately stringent wash conditions described above is hybridization in a solution of 6 X SSC (or 6 X SSPE (standard saline-phosphate-EDTA)), 5 X Denhardt's reagent, 0.5% SDS, 100 μ g/ml denatured, fragmented salmon sperm DNA at a temperature approximately 20 to 25 C below the T_m . If mixed probes are used, it is preferable to use tetramethyl ammonium chloride (TMAC) instead of SSC (Ausubel, 1987, 1999).

To obtain the various above noted naturally occurring IREN-like sequences, standard procedures of screening and isolation of naturally-derived DNA or RNA samples from various tissues may be employed using the natural IREN cDNA or portion thereof as probe (see for example standard procedures set forth in Sambrook et al., 1989).

Likewise, to prepare the above noted various synthetic TRAF-binding protein-like sequences encoding analogs, fragments or derivatives of IREN, a number of standard procedures may be used as are detailed herein below concerning the preparation of such analogs, fragments and derivatives.

A polypeptide or protein "substantially corresponding" to IREN includes not only IREN itself but also polypeptides or proteins that are analogs of IREN.

Analogs that substantially correspond to IREN are those polypeptides in which one or more amino acid of IREN's amino acid sequence has been replaced with another amino acid, deleted and/or inserted, provided that the resulting protein exhibits substantially the same or higher biological activity as IREN.

5 In order to substantially correspond to IREN, the changes in the sequence of the proteins, such as isoforms are generally relatively minor. Although the number of changes may be more than ten, preferably there are no more than ten changes, more preferably no more than five, and most preferably no more than three such changes. While any technique can be used to find potentially biologically active proteins, which
10 substantially correspond to IREN, one such technique is the use of conventional mutagenesis techniques on the DNA encoding the protein, resulting in a few modifications. The proteins expressed by such clones can then be screened for their ability to bind to TRAF proteins (e.g. TRAF2) and to modulate TRAF protein (e.g. TRAF2) activity in modulation/mediation of the intracellular pathways noted above.

15 "Conservative" changes are those changes which would not be expected to change the activity of the protein and are usually the first to be screened as these would not be expected to substantially change the size, charge or configuration of the protein and thus would not be expected to change the biological properties thereof.

Conservative substitutions of IREN include an analog wherein at least one
20 amino acid residue in the polypeptide has been conservatively replaced by a different amino acid. Such substitutions preferably are made in accordance with the following list as presented in Table IA, which substitutions may be determined by routine experimentation to provide modified structural and functional properties of a synthesized polypeptide molecule while maintaining the biological activity
25 characteristic of IREN.

Table IA

	<u>Original</u>	<u>Exemplary</u>
	<u>Residue</u>	<u>Substitution</u>
5	Ala	Gly;Ser
	Arg	Lys
	Asn	Gln;His
10	Asp	Glu
	Cys	Ser
	Gln	Asn
	Glu	Asp
	Gly	Ala;Pro
15	His	Asn;Gln
	Ile	Leu;Val
	Leu	Ile;Val
	Lys	Arg;Gln;Glu
	Met	Leu;Tyr;Ile
20	Phe	Met;Leu;Tyr
	Ser	Thr
	Thr	Ser
	Trp	Tyr
	Tyr	Trp;Phe
25	Val	Ile;Leu

Alternatively, another group of substitutions of IREN are those in which at least one amino acid residue in the polypeptide has been removed and a different residue inserted in its place according to the following Table IB. The types of substitutions which may be made in the polypeptide may be based on analysis of the frequencies of amino acid changes between a homologous protein of different species, such as those presented in Table 1-2 of Schulz et al., G.E., Principles of Protein Structure

Springer-Verlag, New York, NY, 1798, and Figs. 3-9 of Creighton, *T.E.*, *Proteins: Structure and Molecular Properties*, W.H. Freeman & Co., San Francisco, CA 1983. Based on such an analysis, alternative conservative substitutions are defined herein as exchanges within one of the following five groups:

5

TABLE IB

1. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr (Pro, Gly);
2. Polar negatively charged residues and their amides: Asp, Asn, Glu, Gln;
- 10 3. Polar, positively charged residues: His, Arg, Lys;
4. Large aliphatic nonpolar residues: Met, Leu, Ile, Val (Cys); and
5. Large aromatic residues: Phe, Tyr, Trp.

The three amino acid residues in parentheses above have special roles in protein architecture. Gly is the only residue lacking any side chain and thus imparts flexibility to the chain. This however tends to promote the formation of secondary structures other than α -helical. Pro, because of its unusual geometry, tightly constrains the chain and generally tends to promote β -turn-like structures, although in some cases Cys can be capable of participating in disulfide bond formation, which is important in protein folding. Note that Schulz *et al.*, *supra*, would merge Groups 1 and 2, above. Note also that Tyr, because of its hydrogen bonding potential, has significant kinship with Ser, and Thr, etc.

Conservative amino acid substitutions according to the present invention, e.g., as presented above, are known in the art and would be expected to maintain biological and structural properties of the polypeptide after amino acid substitution. Most deletions and substitutions according to the present invention are those which do not produce radical changes in the characteristics of the protein or polypeptide molecule. "Characteristics" is defined in a non-inclusive manner to define both changes in secondary structure, e.g. α -helix or β -sheet, as well as changes in biological activity, e.g., binding to TRAF proteins and/or mediation of TRAF proteins' effect on cell death.

30

Examples of production of amino acid substitutions in proteins which can be used for obtaining analogs of IRENS for use in the present invention include any known

method steps, such as presented in U.S. patent RE 33,653, 4,959,314, 4,588,585 and 4,737,462, to Mark et al.; 5,116,943 to Koths et al., 4,965,195 to Namen et al.; 4,879,111 to Chong et al.; and 5,017,691 to Lee et al.; and lysine substituted proteins presented in U.S. patent No. 4,904,584 (Shaw et al.).

5 Besides conservative substitutions discussed above which would not significantly change the activity of IREN, either conservative substitutions or less conservative and more random changes, which lead to an increase in biological activity of the analogs of IRENS, are intended to be within the scope of the invention.

10 When the exact effect of the substitution or deletion is to be confirmed, one skilled in the art will appreciate that the effect of the substitution(s), deletion(s), etc., will be evaluated by routine binding and cell death assays. Screening using such a standard test does not involve undue experimentation.

15 At the genetic level, these analogs are generally prepared by site-directed mutagenesis of nucleotides in the DNA encoding the IREN, thereby producing DNA encoding the analog, and thereafter synthesizing the DNA and expressing the polypeptide in recombinant cell culture. The analogs typically exhibit the same or increased qualitative biological activity as the naturally occurring protein, Ausubel *et al.*, *Current Protocols in Molecular Biology*, Greene Publications and Wiley Interscience, New York, NY, 1987-1995; Sambrook *et al.*, *Molecular Cloning: A*
20 *Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.

25 Preparation of an IREN mutein in accordance herewith, or an alternative nucleotide sequence encoding the same polypeptide but differing from the natural sequence due to changes permitted by the known degeneracy of the genetic code, can be achieved by site-specific mutagenesis of DNA that encodes an earlier prepared analog or a native version of an IREN. Site-specific mutagenesis allows the production of analogs through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 20 to 25
30 nucleotides in length is preferred, with about 5 to 10 complementing nucleotides on each side of the sequence being altered. In general, the technique of site-specific mutagenesis is well known in the art, as exemplified by publications such as Adelman *et al.*, *DNA* 2:183 (1983), the disclosure of which is incorporated herein by reference.

As will be appreciated, the site-specific mutagenesis technique typically employs a phage vector that exists in both a single-stranded and double-stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage, for example, as disclosed by Messing *et al.*, *Third Cleveland Symposium on Macromolecules and Recombinant DNA*, Editor A. Walton, Elsevier, Amsterdam
5 (1981), the disclosure of which is incorporated herein by reference. These phages are readily available commercially and their use is generally well known to those skilled in the art. Alternatively, plasmid vectors that contain a single-stranded phage origin of replication (Veira *et al.*, *Meth. Enzymol.* 153:3, 1987) may be employed to obtain
10 single-stranded DNA.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector that includes within its sequence a DNA sequence that encodes the relevant polypeptide. An oligonucleotide primer bearing the desired mutated sequence is prepared synthetically by automated DNA/oligonucleotide
15 synthesis. This primer is then annealed with the single-stranded protein-sequence-containing vector, and subjected to DNA-polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, to complete the synthesis of the mutation-bearing strand. Thus, a mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells,
20 such as *E. coli* JM101 cells, and clones are selected that include recombinant vectors bearing the mutated sequence arrangement.

After such a clone is selected, the mutated IREN sequence may be removed and placed in an appropriate vector, generally a transfer or expression vector of the type that may be employed for transfection of an appropriate host.

25 Accordingly, a gene or nucleic acid coding for an IREN protein can also be detected, obtained and/or modified, *in vitro*, *in situ* and/or *in vivo*, by the use of known DNA or RNA amplification techniques, such as PCR and chemical oligonucleotide synthesis. PCR allows for the amplification (increase in number) of specific DNA sequences by repeated DNA polymerase reactions. This reaction can be used as a
30 replacement for cloning; all that is required is knowledge of the nucleic acid sequence. In order to carry out PCR, primers are designed which are complementary to the sequence of interest. The primers are then generated by automated DNA synthesis. Because primers can be designed to hybridize to any part of the gene, conditions can be

created such that mismatches in complementary base pairing can be tolerated. Amplification of these mismatched regions can lead to the synthesis of a mutagenized product resulting in the generation of a peptide with new properties (i.e., site directed mutagenesis). See also, e.g., Ausubel, *supra*, Ch. 16. Also, by coupling complementary

5 DNA (cDNA) synthesis, using reverse transcriptase, with PCR, RNA can be used as the starting material for the synthesis of the extracellular domain of a prolactin receptor without cloning.

Furthermore, PCR primers can be designed to incorporate new restriction sites or other features such as termination codons at the ends of the gene segment to be

10 amplified. This placement of restriction sites at the 5' and 3' ends of the amplified gene sequence allows for gene segments encoding an IREN protein or a fragment thereof to be custom designed for ligation other sequences and/or cloning sites in vectors.

PCR and other methods of amplification of RNA and/or DNA are well known in the art and can be used according to the present invention without undue

15 experimentation, based on the teaching and guidance presented herein. Known methods of DNA or RNA amplification include, but are not limited to polymerase chain reaction (PCR) and related amplification processes (see, e.g., U.S. patent Nos. 4,683,195, 4,683,202, 4,800,159, 4,965,188, to Mullis *et al.*; 4,795,699 and 4,921,794 to Tabor *et al.*; 5,142,033 to Innis; 5,122,464 to Wilson *et al.*; 5,091,310 to Innis; 5,066,584 to

20 Gyllensten *et al.*; 4,889,818 to Gelfand *et al.*; 4,994,370 to Silver *et al.*; 4,766,067 to Biswas; 4,656,134 to Ringold; and Innis *et al.*, eds, *PCR Protocols: A Guide to Method and Applications*) and RNA mediated amplification which uses anti-sense RNA to the target sequence as a template for double stranded DNA synthesis (U.S. patent No. 5,130,238 to Malek *et al.*, with the trade name NASBA); and immuno-PCR which

25 combines the use of DNA amplification with antibody labeling (Ruzicka *et al.*, *Science* 260:487 (1993); Sano *et al.*, *Science* 258:120 (1992); Sano *et al.*, *Biotechniques* 9:1378 (1991)), the entire contents of which patents and reference are entirely incorporated herein by reference.

In an analogous fashion, biologically active fragments of IREN or its isoforms

30 may be prepared as noted above with respect to the analogs of TRAF-binding proteins. Suitable fragments of TRAF-binding proteins are those which retain the TRAF-binding protein capability and which can mediate the biological activity of TRAF proteins or other proteins associated with TRAF proteins directly or indirectly. Accordingly, IREN

As mentioned above, it should be understood that the above IREN, isoforms, fragments, derivatives, muteins etc. of the invention are any proteins which may bind and/or mediate/modulate the activity of any TRAF protein intracellularly. In particular, examples are those proteins which can modulate or mediate the TRAF2-associated intracellular signaling activity, as mentioned above, especially as concerns TRAF2's involvement in modulating NF- κ B activity, in particular, following the interaction between TRAF2 and various members of the TNF/NGF receptor family and/or their associated adapter proteins as detailed above and below. IREN according to the invention and its various isoforms analogs, fragments, etc. (see Examples) which appear to bind TRAF2 very specifically and to have an action in modulating NF- κ B activity, with IREN dominant-negative analogs/muteins modulating this activity, do so.

All the above mentioned modifications are in the scope of the invention provided they preserved the ability of the encoded proteins or polypeptides or their analogs and derivatives thereof, to bind at least the 225-501 amino acid sequence of TRAF2.

All the proteins and polypeptides of the invention by virtue of their capability to bind to TRAF2, are considered as mediators or modulators of TRAF2 signaling. As such, said molecules of the invention have a role in, for example, the signaling process in which the binding of TRAF2 ligand to CD30, CD40, lymphotoxin beta (LT- β) receptor, p55 or p75 TNF receptors, as well as the other receptors and adaptor proteins noted herein above, leads to activation of the transcription factor NF- κ B. Particularly interesting is protein IREN and its isoforms of the invention.

The new clones, proteins, their analogs, fragments and derivatives have a number of possible uses, for example:

(i) They may be used to modulate NF κ B activity, the function of TRAF2 and the receptors to which they bind, in situations where a modulation of function is desired such as in anti-tumor or immuno-stimulatory applications where the TRAF2- induced effects are desired. In this case the proteins of the invention, their analogs, fragments or derivatives, which modulate the TRAF2 or receptors effects, may be introduced to the cells by standard procedures known per se. For example, as the proteins encoded by the DNA clones of the invention are intracellular and they should be introduced only into the cells where the TRAF2 effect is desired, a system for specific introduction of these

CONFIDENTIAL

SECRET

Yet another way of inhibiting the undesired effect is by the recently developed ribozyme approach. Ribozymes are catalytic RNA molecules that specifically cleave RNAs. Ribozymes may be engineered to cleave target RNAs of choice, e.g. the mRNAs encoding the proteins of the invention. Such ribozymes would have a sequence specific for the mRNA of the proteins and would be capable of interacting therewith (complementary binding) followed by cleavage of the mRNA, resulting in a decrease (or complete loss) in the expression of the proteins, the level of decreased expression being dependent upon the level of ribozyme expression in the target cell. To introduce ribozymes into the cells of choice (e.g. those carrying the IREN proteins) any suitable vector may be used, e.g. plasmid, animal virus (retrovirus) vectors, that are usually used for this purpose (see also (i) above, where the virus has, as second sequence, a cDNA encoding the ribozyme sequence of choice). (For reviews, methods etc. concerning ribozymes see Chen et al., 1992; Zhao and Pick, 1993).

(iii) They may be used to isolate, identify and clone other proteins which are capable of binding to them, e.g. other proteins involved in the intracellular signaling process that are downstream of TRAF2. For example, the DNA sequences encoding the proteins of the invention may be used in the yeast two-hybrid system in which the encoded proteins will be used as "bait" to isolate, clone and identify from cDNA or genomic DNA libraries other sequences ("preys") encoding proteins which can bind to the cloned proteins. In the same way, it may also be determined whether the proteins of the present invention can bind to other cellular proteins, e.g. other receptors of the TNF/NGF superfamily of receptors.

(iv) The encoded proteins, their analogs, fragments or derivatives may also be used to isolate, identify and clone other proteins of the same class i.e. those binding to TRAF2 or to functionally related proteins, and involved in the intracellular signaling process. In this application the above noted yeast two-hybrid system may be used, or there may be used a recently developed system employing non-stringent Southern hybridization followed by PCR cloning (Wilks et al., 1989).

(v) Yet another approach to utilize the encoded proteins of the invention, their isoforms analogs, fragments or derivatives is to use them in methods of affinity chromatography to isolate and identify other proteins or factors to which they are

labeled antibody of the present invention to such a specimen. The antibody (or fragment) is preferably provided by applying or by overlaying the labeled antibody (or fragment) to a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the clones, but also its distribution on the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of wide variety of histological methods (such as staining procedures) can be modified in order to achieve such *in situ* detection.

Such assays for the clones of the present invention typically comprise incubating a biological sample, such as a biological fluid, a tissue extract, freshly harvested cells such as lymphocytes or leukocytes, or cells which have been incubated in tissue culture, in the presence of a labeled antibody capably of identifying the encoded proteins, and detecting the antibody by any of a number of techniques well known in the art.

(viii) The encoded proteins of the invention may also be used as indirect modulators of a number of other proteins by virtue of their capability of binding to other intracellular proteins, which other intracellular proteins directly bind yet other intracellular proteins or an intracellular domain of a transmembrane protein.

For the purposes of modulating these other intracellular proteins or the intracellular domains of transmembranal proteins, the proteins of the invention may be introduced into cells in a number of ways as mentioned hereinabove in (ii).

It should also be noted that the isolation, identification and characterization of the proteins of the invention might be performed using any of the well-known standard screening procedures. For example, one of these screening procedures, the yeast two-hybrid procedure which was used to identify the proteins of the invention. Likewise other procedures may be employed such as affinity chromatography, DNA hybridization procedures, etc. as are well known in the art, to isolate, identify and characterize the proteins of the invention or to isolate, identify and characterize additional proteins, factors, receptors, etc. which are capable of binding to the proteins of the invention.

Moreover, the proteins found to bind to the proteins of the invention may themselves be employed, in an analogous fashion to the way in which the proteins of the invention were used as noted above and below, to isolate, identify and characterize other proteins, factors, etc. which are capable of binding to the proteins of the invention-binding proteins and which may represent factors involved further

downstream in the associated signaling process, or which may have signaling activities of their and hence would represent proteins involved in a distinct signaling process.

The DNA sequences and the encoded proteins of the invention may be produced by any standard recombinant DNA procedure (see for example, Sambrook, et al., 1989) in which suitable eukaryotic or prokaryotic host cells are transformed by appropriate eukaryotic or prokaryotic vectors containing the sequences encoding for the proteins. Accordingly, the present invention also concerns such expression vectors and transformed hosts for the production of the proteins of the invention. As mentioned above, these proteins also include their biologically active analogs, fragments and derivatives, and thus the vectors encoding them also include vectors encoding analogs and fragments of these proteins, and the transformed hosts include those producing such analogs and fragments. The derivatives of these proteins are the derivatives produced by standard modification of the proteins or their analogs or fragments, produced by the transformed hosts.

The present invention also relates to pharmaceutical compositions for modulation of the effects mediated by TRAF2. The pharmaceutical compositions comprising, as an active ingredient, any one or more of the following: (i) one or more of the DNA sequences of the invention, or parts of them, subcloned into an appropriate expression vector; (ii) a protein according to the invention, its biologically active fragments, analogs, derivatives or a mixture thereof; (iii) a recombinant animal virus vector encoding for a protein according to the invention, its biologically active fragments, analogs or derivatives.

The pharmaceutical compositions are applied according to the disease to be treated and in amounts beneficial to the patient, depending on body weight and other considerations, as determined by the physician.

As noted above, one of the specific embodiments of the TRAF-binding proteins of the present invention is the TRAF2-binding protein IREN. Based on the findings in accordance with the present invention that IREN binds specifically to TRAF2 and as such is a mediator/modulator of TRAF2 and can thus mediate/modulate TRAF2's activity in NF- κ B activation and hence its possible role in cell survival pathways in ways that TRAF2 functions independently or in conjunction with other proteins (e.g. p55 TNF and p75 TNF receptors, FAS/APO1 receptor, MORT-1, RIP and TRADD) it is

of importance to design drugs which may enhance or inhibit the TRAF2-IREN interaction, as desired. For example, when it is desired to modulate the cell cytotoxicity induced by TNF it would be desired to modulate NF- κ B induction, by modulating the TRAF2-IREN interaction or by modulating TRAF2 and/or IREN specifically. Likewise, 5 for example, when it is desired to modulate the cell cytotoxicity induced by TNF it would be desired to modulate NF- κ B induction by modulating the TRAF2-IREN interaction or by modulating TRAF2- and/or IREN specific NF- κ B modulation. There are many diseases in which such drugs can be of great help. Amongst others, (see above discussion as well) acute hepatitis in which the acute damage to the liver seems to reflect FAS/APO1 receptor-mediated death of the liver cells following induction by the 10 Fas ligand; autoimmune-induced cell death such as the death of the β Langerhans cells of the pancreas, that results in diabetes; the death of cells in graft rejection (e.g., kidney, heart and liver); the death of oligodendrocytes in the brain in multiple sclerosis; and AIDS-inhibited T cell suicide which causes proliferation of the AIDS virus and hence 15 the AIDS disease.

It is possible that IREN or one or more of its possible biologically active isoforms, analogs or fragments may serve as "natural" inhibitors of IREN itself or of the IREN-TRAF2 interaction, and as such serve as modulators of NF- κ B activation. Such modulators may thus be employed as the specific modulators noted above, for example, 20 those modulators to be used when it is desired to modulate the cell cytotoxic effects of TNF. In fact, as exemplified herein below, various IREN analogs and muteins have been isolated in accordance with the present invention, which are capable of modulating the induction of NF- κ B activation mediated by NIK, NEMO, IKK-1 or fragments thereof. And also as mediated by bacterial endotoxin (LPS), phorbol myristate acetate, and the 25 HTLV-1 protein TAX. Likewise, other substances such as peptides, organic compounds, antibodies, etc. may also be screened to obtain specific drugs, which are capable of inhibiting the TRAF2-IREN interaction or the activity of IREN.

In a similar fashion, when it is desired to modulate the NF- κ B activation in various situations as noted above it is possible, for example, to modulate the amount of 30 IREN and/or TRAF2 in cells by various standard methods noted herein above (e.g. introducing DNA encoding IREN and/or TRAF2 into cells to modulate expression, or preparing suitable formulations containing IREN and/or TRAF2 for direct introduction

into cells, or any other way known to those of skill in the art). Likewise, other substances such as peptides, organic compounds, etc. may also be screened to obtain specific drugs, which are capable of enhancing the activity of IREN or of enhancing the TRAF2- IREN interaction.

5 A non-limiting example of how peptide modulators of the IREN-TRAF2 interaction would be designed and screened is based on previous studies on peptide inhibitors of ICE or ICE-like proteases, the substrate specificity of ICE and strategies for epitope analysis using peptide synthesis. The minimum requirement for efficient cleavage of a peptide by ICE was found to involve four amino acids to the left of the
10 cleavage site with a strong preference for aspartic acid in the P₁ position and with methylamine being sufficient to the right of the P₁ position (Sleath et al., 1990; Howard et al., 1991; Thornberry et al., 1992). Furthermore, the fluorogenic substrate peptide (a tetrapeptide), acetyl-Asp-Glu-Val-Asp-a-(4-methyl-coumaryl-7-amide) abbreviated Ac-DEVD-AMC, corresponds to a sequence in poly (ADP-ribose) polymerase (PARP)
15 found to be cleaved in cells shortly after FAS-R stimulation, as well as other apoptotic processes (Kaufmann, 1989; Kaufmann et al., 1993; Lazebnik et al., 1994), and is cleaved effectively by CPP32 (a member of the CED3/ICE protease family) and MACH proteases.

As Asp in the P₁ position of the substrate appears to be important, tetrapeptides
20 having Asp as the fourth amino acid residue and various combinations of amino acids in the first three residue positions can be rapidly screened for binding to the active site of the proteases using, for example, the method developed by Geysen (Geysen, 1985; Geysen et al., 1987) where a large number of peptides on solid supports were screened for specific interactions with antibodies. The binding of MACH proteases to specific
25 peptides can be detected by a variety of well known detection methods within the skill of those in the art, such as radiolabeling, etc. This method of Geysen's was shown to be capable of testing at least 4000 peptides each working day.

In a similar way the exact binding region or region of homology which determines the interaction between TRAF2 and IREN (or any other TRAF protein and
30 TRAF-binding protein) can be elucidated and then peptides may be screened which can serve to block this interaction, e.g. peptides synthesized having a sequence similar to that of the binding region or complementary thereto which can compete with natural IREN (or TRAF-binding protein) for binding to TRAF2 (or TRAF).

Since it may be advantageous to design peptide inhibitors that selectively inhibit TRAF2-IREN (or TRAF-TRAF binding protein) interactions without interfering with physiological cell death processes in which other members of the intracellular signaling pathway are involved, e.g. MACH proteases of the cell death pathway, which are members of the CED3/ICE family of proteases, the pool of peptides binding to TRAF2 (or TRAF) or IREN (or TRAF-binding proteins) in an assay such as the one described above can be further synthesized as a fluorogenic substrate peptide to test for selective binding to such other proteins to select only those specific for TRAF2/IREN (or TRAF/TRAF-binding protein). Peptides, which are determined to be specific for, for example, TRAF2/IREN, can then be modified to enhance cell permeability and inhibit the activity of TRAF2 and/or IREN either reversibly or irreversibly. Thornberry et al. (1994) reported that a tetrapeptide (acyloxy) methyl ketone Ac-Tyr-Val-Ala-Asp-CH₂OC (O)-[2,6-(CF₃)₂] Ph was a potent inactivator of ICE. Similarly, Milligan et al. (1995) reported that tetrapeptide inhibitors having a chloromethylketone (irreversibly) or aldehyde (reversibly) groups inhibited ICE. In addition, a benzyloxycarboxyl-Asp-CH₂OC (O) -2,6-dichlorobenzene (DCB) was shown to inhibit ICE (Mashima et al., 1995). Accordingly, in an analogous way, tetrapeptides that selectively bind to, for example, TRAF2 or IREN, can be modified with, for example, an aldehyde group, chloromethylketone, (acyloxy) methyl ketone or a CH₂OC (O)-DCB group to create a peptide inhibitor of TRAF2/IREN activity. Further, to improve permeability, peptides can be, for example, chemically modified or derivatized to enhance their permeability across the cell membrane and facilitate the transport of such peptides through the membrane and into the cytoplasm. Muranishi et al. (1991) reported derivatizing thyrotropin-releasing hormone with lauric acid to form a lipophilic lauroyl derivative with good penetration characteristics across cell membranes. Zacharia et al. (1991) also reported the oxidation of methionine to sulfoxide and the replacement of the peptide bond with its ketomethylene isoester (COCH₂) to facilitate transport of peptides through the cell membrane. These are just some of the known modifications and derivatives that are well within the skill of those in the art.

Furthermore, drug or peptide inhibitors, which are capable of inhibiting the activity of, for example, IREN by inhibiting the IREN-TRAF2 interaction and likewise,

example, where murine mAbs have higher yields from hybridomas but higher immunogenicity in humans, such that human/murine chimeric mAbs are used. Chimeric antibodies and methods for their production are known in the art (Cabilly et al., *Proc. Natl. Acad. Sci. USA* 81:3273-3277 (1984); Morrison et al., *Proc. Natl. Acad. Sci. USA* 81:6851-6855 (1984); Boulianne et al., *Nature* 312:643-646 (1984); Cabilly et al., European Patent Application 125023 (published November 14, 1984); Neuberger et al., *Nature* 314:268-270 (1985); Taniguchi et al., European Patent Application 171496 (published February 19, 1985); Morrison et al., European Patent Application 173494 (published March 5, 1986); Neuberger et al., PCT Application WO 8601533, (published March 13, 1986); Kudo et al., European Patent Application 184187 (published June 11, 1986); Sahagan et al., *J. Immunol.* 137:1066-1074 (1986); Robinson et al., International Patent Application No. WO8702671 (published May 7, 1987); Liu et al., *Proc. Natl. Acad. Sci USA* 84:3439-3443 (1987); Sun et al., *Proc. Natl. Acad. Sci USA* 84:214-218 (1987); Better et al., *Science* 240:1041-1043 (1988); and Harlow and Lane, ANTIBODIES: A LABORATORY MANUAL, supra. These references are entirely incorporated herein by reference.

An anti-idiotypic (anti-Id) antibody is an antibody which recognizes unique determinants generally associated with the antigen-binding site of an antibody. An Id antibody can be prepared by immunizing an animal of the same species and genetic type (e.g. mouse strain) as the source of the mAb to which an anti-Id is being prepared. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody by producing an antibody to these idiotypic determinants (the anti-Id antibody). See, for example, U.S. Patent No. 4,699,880, which is herein entirely incorporated by reference.

25 The anti-Id antibody may also be used as an "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody. The anti-anti-Id may be epitopically identical to the original mAb, which induced the anti-Id. Thus, by using antibodies to the idiotypic determinants of a mAb, it is possible to identify other clones expressing antibodies of identical specificity.

30 Accordingly, mAbs generated against IREN, its isoforms, analogs, fragments or derivatives of the present invention may be used to induce anti-Id antibodies in suitable animals, such as BALB/c mice. Spleen cells from such immunized mice are used to produce anti-Id hybridomas secreting anti-Id mAbs. Further, the anti-Id mAbs can be

The antibodies (or fragments thereof) useful in the present invention may be employed histologically, as in immunofluorescence or immunoelectron microscopy, for *in situ* detection of the IREN proteins of the present invention. *In situ* detection may be accomplished by removing a histological specimen from a patient, and providing the labeled antibody of the present invention to such a specimen. The antibody (or fragment) is preferably provided by applying or by overlaying the labeled antibody (or fragment) to a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the IREN proteins but also its distribution on the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of wide variety of histological methods (such as staining procedures) can be modified in order to achieve such *in situ* detection.

20 The biological sample may be treated with a solid phase support or carrier such as nitrocellulose, or other solid support or carrier which is capable of immobilizing cells, cell particles or soluble proteins. The support or carrier may then be washed with suitable buffers followed by treatment with a labeled antibody in accordance with the present invention, as noted above. The solid phase support or carrier may then be
25 washed with the buffer a second time to remove unbound antibody. The amount of bound label on said solid support or carrier may then be detected by conventional means.

material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support or carrier configuration may be spherical, as in a bead, cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports or carriers include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

The binding activity of a given lot of antibody, of the invention as noted above, may be determined according to well-known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

Other such steps as washing, stirring, shaking, filtering and the like may be added to the assays as is customary or necessary for the particular situation.

One of the ways in which an antibody in accordance with the present invention can be labeled is by linking the same to an enzyme and used in an enzyme immunoassay (EIA). This enzyme, in turn, when later exposed to an appropriate substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholin-esterase. The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

Detection may be accomplished using any of a variety of other immunoassays. For example, by radioactive labeling the antibodies or antibody fragments, it is possible to detect R-PTPase through the use of a radioimmunoassay (RIA). A good description of RIA may be found in Laboratory Techniques and Biochemistry in Molecular Biology, by Work, T.S. et al., North Holland Publishing Company, NY (1978) with particular reference to the chapter entitled "An Introduction to Radioimmune Assay and Related

In another type of "sandwich" assay, which may also be useful with the antigens of the present invention, the so-called "simultaneous" and "reverse" assays are used. A simultaneous assay involves a single incubation step as the antibody bound to the solid support or carrier and labeled antibody are both added to the sample being tested at the same time. After the incubation is completed, the solid support or carrier is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody associated with the solid support or carrier is then determined, as it would be in a conventional "forward" sandwich assay.

In the "reverse" assay, stepwise addition first of a solution of labeled antibody to the fluid sample followed by the addition of unlabeled antibody bound to a solid support or carrier after a suitable incubation period is utilized. After a second incubation, the solid phase is washed in conventional fashion to free it of the residue of the sample being tested and the solution of unreacted labeled antibody. The determination of labeled antibody associated with a solid support or carrier is then determined as in the "simultaneous" and "forward" assays.

As mentioned above, the present invention also relates to pharmaceutical compositions comprising recombinant animal virus vectors encoding the IREN protein, which vector also encodes a virus surface protein capable of binding specific target cell (e.g., cancer cells) surface proteins to direct the insertion of the IREN protein sequences into the cells. Further pharmaceutical compositions of the invention comprises as the active ingredient (a) an oligonucleotide sequence encoding an anti-sense sequence of the IREN protein sequence, or (b) drugs that block the IREN protein- TRAF interaction.

Pharmaceutical compositions according to the present invention include a sufficient amount of the active ingredient to achieve its intended purpose. In addition, the pharmaceutical compositions may contain suitable pharmaceutically acceptable

carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically and which can stabilize such preparations for administration to the subject in need thereof as are well known to those of skill in the art.

5 The IREN protein and its isoforms or isotypes are suspected to be expressed in different tissues at markedly different levels and apparently also with different patterns of isotypes in an analogous fashion to the expression of various other proteins involved in the intracellular signaling pathways as indicated in the above listed co-owned co-pending patent applications. These differences may possibly contribute to the
10 tissue-specific features of response to the Fas/APO1-ligand and TNF. As in the case of other CED3/ICE homologs (Wang et al., 1994; Alnemri et al., 1995), the present inventors have previously shown (in the above mentioned patent applications) that MACH isoforms that contain incomplete CED3/ICE regions (e.g., MACH α 3) are found to have an inhibitory effect on the activity of co-expressed MACH α 1 or MACH α 2
15 molecules; they are also found to block death induction by Fas/APO1 and p55-R. Expression of such inhibitory isoforms in cells may constitute a mechanism of cellular self-protection against Fas/APO1- and TNF-mediated cytotoxicity. The wide heterogeneity of MACH isoforms, which greatly exceeds that observed for any of the other proteases of the CED3/ICE family, should allow a particularly fine-tuning of the
20 function of the active MACH isoforms.

In accordance with the present invention there have also been isolated analogs/mutants of the TRAF2-binding protein IREN. Some of these IREN analogs/mutants (see above and see Examples below), such as deletion mutants of IREN modulate NF- κ B activation. Hence, as noted above, the IREN proteins or possible
25 isoforms may have varying effects in different tissues as regards their interaction with TRAF proteins and their influence thereby on the activity of the TRAF proteins, or intracellular signaling mediated by the TRAF proteins.

It is also possible that some of the possible IREN isoforms serve other functions. For example, IREN or some IREN analogs, or isoforms may also act as docking sites for
30 molecules that are involved in other, non-cytotoxic effects of, for example, Fas/APO1 and TNF receptors via interaction with TRAF2 or even independently of TRAF2.

[illegible]

The present invention also concerns proteins or other ligands which can bind to the IREN proteins of the invention and thereby modulate/mediate the activity of the IREN proteins. Such proteins or ligands may be screened, isolated and produced by any of the above mentioned methods. For example, there may be isolated a number of new ligands, including proteins, capable of binding to the IREN proteins of the invention (such new proteins/ligands excluding the known TRAF2 and TRAF1).

As detailed above, such new IREN protein-binding proteins/ligands, e.g. IREN-binding proteins, may serve as, for example, inhibitors or enhancers of IREN-mediated activity or the activity mediated by the, for example, TRAF2-IREN interaction, and as such will have important roles in various pathological and other situations as detailed above. Another function of such IREN protein-binding proteins/ligands would be to serve as specific agents for the purification of the IREN proteins by, for example, affinity chromatography, these new binding proteins/ligands being attached to the suitable chromatography matrices to form the solid or affinity support/matrix through which a solution, extract or the like, containing e.g. IREN, will be passed and in this way to facilitate the purification thereof. Such methods of affinity chromatography are now well known and generally standard procedures of the art.

Likewise, all of the above mentioned IREN proteins, analogs, fragments, isoforms and derivatives of the present invention may be used to purify by affinity

The invention will now be described in more detail in the following non-limiting examples and the accompanying drawings:

It should also be noted that the procedures of:

i) two-hybrid screen and two-hybrid β -galactosidase expression test; (ii) induced expression, metabolic labeling and immunoprecipitation of proteins; (iii) *in vitro* binding; (iv) assessment of the cytotoxicity; and (v) Northern and sequence analyses, as well as other procedures used in the following Examples have been detailed in previous publications by the present inventors in respect of other intracellular signaling proteins and pathways (see, for example, Boldin et al., 1995a, 1995b, and Boldin et al. 1996). These procedures also appear in detail in the co-owned co-pending Israel Application Nos. 114615, 114986, 115319, 116588, 117932, and 120367 as well as the corresponding PCT application No. PCT/US96/10521). Accordingly, the full disclosures of all these publications and patent applications are included herein in their entirety and at least as far as the detailed experimental procedures are concerned.

20 **EXAMPLES**

Materials and Methods

i) cDNA libraries

a) B-cell cDNA library

Oligo dT primed library constructed from human B cells was used (Durfee et al., 1993). The cDNAs of the library were inserted into the XhoI site of the pACT based vector pSE1107 in fusion with GAL4 activation domain.

b) λ gt10 testis cDNA library

A cDNA library from human testis was used. The library is a random hexanucleotide primed library with an average insert size of 200 to 400 bp.

ii) Yeast strains

Two yeast strains were used as host strains for transformation and screening: HF7c strain that was used in the two hybrid screen and SFY526 strain that was used in the β -galactosidase assays. Both strains carry the auxotrophic markers *trp1* and *leu2*, namely these yeast strains cannot grow in minimal synthetic medium lacking tryptophan and leucine, unless they are transformed by a plasmid carrying the wild-type versions of these genes (*TRP1*, *LEU2*). The two yeast strains carry deletion mutations in their *GAL4* and *GAL80* genes (*gal4-542* and *gal80-538* mutations, respectively).

SFY526 and HF7c strains carry the *lacZ* reporter in their genotypes; in SFY526 strain fused to the UAS and the TATA portion of *GAL1* promoter, and in HF7c three copies of the *GAL4* 17-mer consensus sequence and the TATA portion of the *CYC1* promoter are fused to *lacZ*. Both *GAL1* UAS and the *GAL4* 17-mers are responsive to the *GAL4* transcriptional activator. In addition, HF7c strain carries the *HIS3* reporter fused to the UAS and the TATA portion of *GAL1* promoter.

iii) Cloning of human TRAF2

The human TRAF2 was cloned by PCR from an HL60 cDNA library (for TRAF2 sequence and other details see Rothe et al., 1994; Rothe et al., 1995a; Cheng et al., 1996; Hsu et al., 1996; and Wallach, 1996). The primers used were: a) 30-mer forward primer CAGGATCCTCATGGCTGCAGCTAGCGTGAC (SEQ ID NO:1) corresponding to the coding sequence of hTRAF2 starting from the codon for the first Methionine (underlined) and including a linker with BamHI site. b) 32-mer reverse primer GGTCGACTTAGAGCCCTGTCAGGTCCACAATG (SEQ ID NO:2) that includes hTRAF2 gene stop codon (underlined) and a Sall restriction site in its linker. PCR program comprised of an initial denaturation step 2 min. at 94°C followed by 30 cycles of 1 min. at 94°C, 1 min. at 64°C, 1 min. and 40 sec. at 72°C. The amplified human TRAF2 was then inserted into the BamHI - Sall sites of pGBT9 vector in conjunction with GAL 4 DNA Binding domain.

iv) Two hybrid screen of B-cell library

The two hybrid screen is a technique (see details in above mentioned publications and patent applications) used in order to identify factors that are associated

15 Positive clones picked up in the two hybrid screen were subjected to lacZ color development test in SFY526 yeast cells, following Clontech Laboratories' manual (for details see above mentioned publications and patent applications). In brief, transformants were allowed to grow at 30⁰C for 2-4 days until reaching about 2 mm in diameter, then were transferred onto Whatman filters. The filters went through a
20 freeze/thaw treatment in order to permeabilize the cells, then soaked in a buffer (16.1 mg/ml Na₂HPO₄·7H₂O; 5.5 mg/ml NaH₂PO₄·H₂O; 0.75 mg/ml KCl; 0.75 mg/ml MgSO₄·7H₂O, pH=7) containing 0.33 mg/ml X-gal and 0.35 mM β-mercaptoethanol. Colonies were monitored for development of blue color which is an indication for induction of β-galactosidase.

Two kinds of expression vectors were constructed:

- a) A pUHD10-3 based vectors containing the open reading frame (ORF) of IREN in fusion with the Hemagglutinin (HA) epitope.
- b) A pUHD10-3 based vector into which FLAG octapeptide sequence was introduced just in front of cloned TRAF2, hereby named FLAG/B6/TRAF2.

color that developed was an indication for yeast colonies that contain cDNA encoding a protein or polypeptide that binds to TRAF2.

6 independent clones were identified that encoded the novel protein IREN by their ability to grow on 3AT plates and to induce LacZ as measured in the color test. Of all the positive clones checked, two were cDNAs coding for known proteins; TRAF2 itself that is capable of self-associating and forming homodimers, and the lymphotoxin beta receptor whose intracellular domains were shown to bind TRAF2.

The positive clones were further analysed in a binding specificity test, namely analysed for their interaction with irrelevant baits. As shown in Table II, IREN reacted only with TRAF2 and TRAF1 and did not bind to any one of a number of irrelevant proteins analysed such as lamin, and Cyclin D. IREN did not bind the intracellular domain of the p55 and p75 TNF receptors, MORT, NIK, NIK mutant ₁₋₄₀₀, nor A20.

In order to narrow down the region on the TRAF2 molecule which interacts with IREN two additional constructs were made. One construct comprising the N-terminal part of the TRAF2 molecule, amino acids 1 to 224 designated RING ₁₋₂₂₄ comprising the Ring finger and the zinc finger motifs. The second construct included only the C-terminal part of TRAF2, amino acids 225 to 501, covering the "TRAF-domain" as well as an additional 42 amino acids. These two constructs were used as baits in two hybrid tests. The results clearly show that IREN did not interact with the construct comprising amino acids 1 to 224 of the TRAF2 molecule, they did however bind to the C-terminal construct comprising the "TRAF domain" with the same efficiency as they bound to the full length TRAF2 (Table II). Deletion analysis demonstrated that the TRAF2 binding region in IREN and its isoforms is confined to the region between amino acids 198 and 388 thereof (Table II).

25

Table II Yeast 2 hybrid test for IREN interactions

Bait	Prey	Interaction
TRAF2	IREN	+++
TRAF2 ₂₂₅₋₅₀₁	IREN	+++
RING ₁₋₂₂₄	IREN	-
TRAF2	IREN ₁₋₁₉₇	-
Lamin	IREN ₁₋₁₉₇	-
TRAF2	IREN ₁₉₈₋₃₈₈	+++
Lamin	IREN ₁₉₈₋₃₈₈	-
TRAF2	IREN ₃₉₈₋₅₄₁	+/-
Lamin	IREN ₃₉₈₋₅₄₁	+/-
TRAF2	IREN ₁₉₈₋₅₄₁	+++
Lamin	IREN ₁₉₈₋₅₄₁	-
TRAF2	IREN 10B	++
IREN 10B	IREN 10B	++
IREN 10B	IREN	-
Lamin	IREN 10B	-
Lamin	IREN	-
CycD	IREN	-
p75IC	IREN	-

p55IC	IREN	-
MORT	IREN	-
TRAF3	IREN	-
NIK	IREN	-
NIK 1-400	IREN	-
TRAF1	IREN	+++
A20	IREN	-
TRAF6	IREN	-

The open reading frame of IREN cDNA encodes a protein of 541 amino acid. The cDNA also contains a short 3'UTR as well as poly(A)(Fig. 3A and 3B).

5 The 5' domain of IREN open reading frame (ORF) was found to contain a region which is homologous to one other known protein (ID: U73941, cloned in a 2-hybrid screen for Rap2 binding proteins (Janoueix-Lerosey I et al 1998) as well as to additional unknown proteins found in the databases: two human gene (KIAA0871, KIAA0842) and one C. Elegans gene (ID CAA21666).

10 The sequence of IREN was found to contain a peptide sequence [IDSLSL 326-331] which is also present within the 51 amino acid domain spanning amino acids 769 to 820 of NIK which is essential for IKK-1 binding to NIK in a 2-hybrid assay and NF-kB activation by NIK overexpression (data not shown).

Example 2: Further studies and functional characteristics of IREN

15 IREN cDNA fused to an HA epitope was expressed in the 293 human kidney cell lines using a pcDNA3 based vector containing the ORF of IREN in fusion with the Hemagglutinin (HA) epitope. IREN was then immunoprecipitated with anti HA

antibodies. Cells were transfected with the IREN-HA fusion protein using a standard calcium-phosphate method (Method in, for example, Current Protocols in Molecular Biology, eds. Ausubel, F.M et al.). Cells were then grown for 24 hrs. in Dulbecco's Modified Eagle's Medium (DMEM) plus 10% calf serum. At the end of the incubation time, cells were lysed in radioimmune precipitation buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonident P-40, 1% deoxycholate, 0.1% SDS, and 1 mM EDTA; 1 ml/ 5x10⁵ cells), and the lysate was precleared by incubation with irrelevant rabbit antiserum and Protein G-Sepharose beads (Pharmacia, Sweden). Immunoprecipitation was performed by 1-hour incubation at 4°C of aliquots of the lysate with anti-HA (clone 12CA5 (Field, J. et al., 1988) monoclonal antibodies. The expressed proteins were analysed on an SDS-PAGE gel followed by Western Blot with anti HA antibodies. The protein encoded by IREN thus appears as a band of approximately 60kDa.

Studies of IREN effect on NF-κB activation were performed using the reporter gene assay. 293 EBNA cells were co-transfected with the pcDNA3 vector containing HIV LTR linked to the luciferase reporter gene, together with either the pcDNA3 plasmid containing IREN cDNA alone, or with a pcDNA3 plasmid containing the cDNA encoding the following proteins: IKK-1, full length NEMO, C-terminal deletion of NEMO, NIK, kinase deficient mutant of NIK (NIKmut), a C terminal deletion mutant of IREN (IREN₁₋₁₉₇) or an N-terminal deletion mutant of IREN (IREN₁₉₈₋₅₄₁).

Transfection was done using a standard calcium-phosphate method (Method in, for example, Current Protocols in Molecular Biology, eds. Ausubel, F.M et al.) as described in the above Material and methods (vii).

In co-transfection with murine IKK-1, a known substrate for NIK enzymatic activity (Regnier CH, et al 1997), human IREN was found to efficiently induce NF-κB in 293 cells as determined by the luciferase assay (see Fig. 10).

Co-transfection of a C-terminal deletion mutant of NEMO (ΔNEMO amino acids 1-309) which is reportedly able to block enzymatic activity of IKKs (Rothwarf DM, et al. 1998], was found to inhibit NF-κB induced by IREN and IKK1 co-transfection (Fig. 10).

The activity of NF- κ B induced by IREN and IKK1 co-transfection was comparable to that induced by co-expression of full size NEMO and IKK1. NEMO was not able to further potentiate NF- κ B induced by IREN and IKK1 (Fig. 10).

5 Unlike Δ NEMO, cotransfection of a kinase-deficient mutant of NIK (NIKmut, amino acids (see co-pending co-owned Patent Application WO 97/37016, Malinin et al. 1996) was not able to block NF- κ B induction by cotransfection of IREN and IKK1 (Fig. 10).

IREN co-expressed at a 2:1 fold ratio with NIK DNA effectively potentiates induction of NF- κ B. Co-expression of full-size NEMO with NIK blocks NF- κ B induced by the latter. This inhibition could be reversed by expression of IREN (Fig. 10). As it was shown earlier (see co-pending co-owned Patent Application WO 97/37016, Malinin et al. 1996) NIKmut effectively blocks NF- κ B induced by CD120a overexpression. This effect was not altered by co-expression of IREN (Fig. 10).

15 Taken together the abovementioned data lead to the suggestion that IREN acts within the NF- κ B signalling pathway, acting downstream to NIK but upstream to NEMO and IKK1 and could be a modulator of the interaction between NIK and IKK-1.

It was therefore hypothesized that some deletion mutant of IREN might interfere with the signal flow from NIK kinase to the NEMO-IKK complex. The C terminal deletion mutant IREN₁₋₁₉₇ did not have any effect on NIK-induced NF- κ B activation (data not shown). However an N-terminal deletion mutant of IREN (IREN Δ N; IREN₁₉₈₋₅₄₁) profoundly inhibited NIK-induced NF- κ B, to the extent comparable to that of NEMO (Fig. 10).

Example 3: Kinase Assay

25 293-T cells (2×10^6) were transfected with pcFLAG CHUK (encoding murine IKK1) alone or in combination with pcNIK, pc20.4 (encoding the NEMO protein) or pcHIS-IREN (encoding His tagged-IREN), or pcHIS-IREN Δ N (pcHIS-IREN₁₉₈₋₅₄₁ encoding a His tagged N terminal deletion mutant of IREN that acts as a dominant negative). 24 h post transfection cells were harvested, lysed in lysis buffer containing
30 1% NP-40, 50 mM Hepes pH-7.5, 100 mM NaCl, 10% glycerol, 1mM EDTA, 20 mM

b-glycerophosphate, 20 mM PNPP, 1 mM Na₃VaO₄, 1 mM NaF, 1 mM Na-Metabisulfite, 1 mM Bezamidine, 1 mM DTT, "Complete" protease inhibitors (Boehringer).

Cell debris was then removed by centrifugation. Following addition of NaCl to
 5 up to 250 mM, proteins were immunoprecipitated with monoclonal anti FLAG
 antibodies, washed thoroughly in washing buffer containing lysis buffer with 0.1%
 NP-40 and 250 mM NaCl, and eluted with 30 µl wash buffer containing 1 mg/ml FLAG
 peptide. Aliquots of the eluates were used for an *in-vitro* kinase reactions with E. coli
 produced GST-IκB as substrate, in the presence of ³²P-gamma ATP in kinase buffer
 10 containing 50 mM β-glycerophosphate, 2 mM DTT, 20 mM MgCl₂, 1 mM Na₃ VaO₄,
 1 mM EDTA /EGTA. The reactions were separated by SDS-PAGE and phosphorylation
 of proteins was detected after exposure to X-Ray film. As control, amount of protein in
 the lysate was determined by western blot with anti FLAG antibody.

The N terminal deletion mutant of IREN was found to act as a dominant
 15 negative molecule and to block IKK-1 activity in the kinase assay when IREN and
 IKK-1 were coexpressed with NEMO.

Overexpression of IKK1 and NEMO, but not of IKK1 alone, induces robust
 kinase activity of IKK1 (as assessed by autophosphorylation and by phosphorylation of
 E.coli produced GST-IkappaB fusion protein). Coexpression of IREN₁₉₈₋₅₄₁ with IKK1
 20 and NEMO results in a significant decrease in activity (Fig. 11) without affecting the
 IKK1 and NEMO expression level. Full size IREN did not have such an effect (Fig. 11,
 middle lane).

Example 4: Cloning and sequencing of IREN-10B and IREN-E

25 In order to identify splice variants of IREN, a phage cDNA library derived from
 the abovementioned MCF7 cell line was screened with the first 600bp of IREN as
 probe. Two independent clones were identified which appeared to be two different
 variants of IREN. These two clones are identical to IREN in their first 5' 1595 bp and
 have additional coding sequences at the 3-prime end. This region contains a PX domain
 30 – a conservative domain of unknown function (presumably a protein-protein interaction
 domain) that is also found in some signalling molecules, including PI3-kinase. In clone
 10B and clone E the PX domain is flanked by two short identical regions. The region

downstream to these regions is different in the two clones. For a comparison of the two splice variants to IREN see Fig. 9.

Provisional sequencing of the 5-prime UTR (from the beginning of the sequence up to the first ATG with Kozak sequence) indicated these sequences were identical in IREN and in IREN-10B and IREN-E isoforms.

The region of TRAF2 binding is mapped to IREN₁₉₈₋₃₈₈, which is identical in all three splice isoforms shown (Fig. 9). Accordingly, IREN 10B also interacted with TRAF2 in the two-hybrid assay. Although no self-association of IREN was observed, IREN 10B did self-associate in the two-hybrid test, whereas, it did not interact with IREN (Table II).

A deletion mutant of IREN 10B lacking the PX domain, but including a coiled coil motif not present in IREN, was also able to self associate. This indicates that this coiled coil domain is responsible for self interaction of IREN 10B.

Example 5: Proteins interacting with IREN 10B and IREN

A B cell library was screened with IREN 10B using the yeast two hybrid system as described above to identify additional proteins interacting with IREN 10B. Three such proteins were identified that interacted strongly and specifically with IREN 10B:

1) The mu 1 subunit of the clathrin assembly protein 2 (AP50, CLAPM1; gene bank accession numbers U36188), which interacted strongly with IREN 10B, but only weakly with IREN.

2) The FB1 or Amida gene, which interacted strongly and specifically both with IREN 10B as well as with IREN. This gene was initially identified as a sequence fused to the E2A gene in childhood pre-B leukemia cells (Brambilla et al, Leukemia 13 (3), 369 - 375, 1999). It was recently shown to induce apoptosis upon overexpression. It is localized in the nucleus and is involved in nuclear translocation of a neuron specific immediate early gene called Arc (Irie et al, J. Biol. Chem 275, (2000) 2647 - 2653).

3) The TRAX gene, which interacted strongly with IREN 10B, but only very weakly with IREN. This gene is highly homologous to the DNA binding protein Translin and may be involved in nuclear localisation of Translin (Aoki et al, FEBS Lett 401, 109 - 112, 1997).

found in other chromosomal locations mentionned above are found in the EST databank, demonstrating that both closely related isoforms are active genes (Figure 13 B).

REFERENCES

1. Adelman et al., (1983) DNA 2, 183.
2. Alnemri, E.S. et al. (1995) J. Biol. Chem. 270, 4312-4317.
- 5 3. Arch RH et al (1998). Genes Dev. Sep 15;12(18):2821-30
4. Arch, R.H. and C.B. Thompson. (1998) B. *Mol. Cell. Biol.* 18, 558-565.
5. Ausubel, F.M. et al. eds., Current Protocols in Molecular Biology.
6. Baeuerle, P. A., and Henkel, T. (1994) Annu Rev Immunol.
7. Bazan, J. F. (1993). Current Biology 3, 603-606.
- 10 8. Berberich, I., Shu, G. L., and Clark, E. A. (1994). J Immunol 153, 4357-66.
9. Beutler, B., and van Huffel, C. (1994). Science 264, 667-8.
10. Blank, V., Kourilsky, P., and Israel, A. (1992). Trends Biochem. Sci 17, 135-40.
11. Boldin, M.P. et al. (1995a) J. Biol. Chem. 270, 337-341.
12. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and
- 15 Wallach, D. (1995b). J. Biol. Chem. 270, 7795-7798.
13. Boldin, M.P. et al. (1996) Cell 85, 803-815.
14. Born TL et al. (1998) J Biol Chem. 273, 29445-50.
15. Cao, Z. et al. (1996a) Nature 383, 443-446.
16. Cao, Z. et al. (1996b) Science 271, 1128-1131.
- 20 17. Chen, C.J. et al. (1992) Ann. N.Y. Acad. Sci. 660:271-273.
18. Cheng, G., Cleary, A.M., Ye, Z-s., Hong, D.I., Lederman, S. and Baltimore, D.
(1995) Science 267:1494-1498.
19. Cheng, G. and Baltimore, D. (1996) Genes Dev. 10, 963-973.
20. Chinnalyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. (1995) Cell 81,
- 25 505-512.
21. Creighton, T.E., Proteins : Structure and Molecular Properties, W.H. Freeman &
Co., San Francisco, Ca. 1983.
22. Croston, G. E., Cao, Z., and Goeddel, D. V. (1995). J Biol Chem 270, 16514-7.
23. DiDonato, J. A., Mercurio, F., and Karin, M. (1995). Mol Cell Biol 15, 1302-11.
- 30 24. Duckett, C.S., R.W. Gedrich, M.C. Gilfillan, and C.B. Thompson. (1997) *Mol.*
Cell. Biol. 17, 1535-1542
25. Durfee, T. et al. (1993) Genes Dev. 7:555-569.

26. Field, J. et al. (1988) *Mol. Cell Biol.* 8:2159-2165.
27. Geysen, H.M. (1985) *Immunol. Today* 6, 364-369.
28. Geysen, H.M. et al. (1987) *J. Immunol. Meth.* 102, 259-274.
29. Gilmore, T. D., and Morin, P. J. (1993). *Trends Genet* 9, 427-33.
- 5 30. Gossen, M. and Bujard, M. (1992) *PNAS* 89:5547-5551.
31. Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Baxeiner, B., Georgopoulos, S., Lesslauer, W., Kollias, G., Pfizenmaier, K., and Scheurich, P. (1995). *Cell* 83, 793-802.
32. Grilli, M., Chiu, J. J., and Lenardo, M. J. (1993). *Int RevCytol.*
- 10 33. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988). *Science* 241, 42-52.
34. Hibi, M., Lin, A. Smeal, T. Minden, A. and Karin M. (1993) *Genes & Dev.* 7, 2135-2148
35. Howard, A.D. et al. (1991) *J. Immunol.* 147, 2964-2969.
36. Hsu, H., Shu, H.-B., Pan, M.-G., and Goeddel, D. V. (1996). *Cell* 84, 299-308.
- 15 37. Hsu, H., Xiong, J., and Goeddel, D. V. (1995). *Cell* 81, 495-504.
38. Ishida T et al. (1996a) *Proc Natl Acad Sci U S A.* 93, 9437-42.
39. Ishida T et al. (1996b) *J Biol Chem.* 271, 28745-8.
40. Janoueix-Lerosey I et al *Eur J Biochem* (1998) Mar 1;252(2):290-8
41. Kanakaraj P et al (1999) *J Exp Med* 189, 1129-38
- 20 42. Kaufmann, S.H. (1989) *Cancer Res.* 49, 5870-5878.
43. Kaufmann, S.H. (1993) *Cancer Res.* 53, 3976-3985.
44. Lalmanach-Girard, A. C., Chiles, T. C., Parker, D. C., and Rothstein, T. L. (1993). *J Exp Med* 177, 1215-1219.
45. Lazebnik, Y.A. et al. (1994) *Nature* 371, 346-347
- 25 46. Lee, S.Y., C.G. Park, and Y. Choi. 1996 *J. Exp. Med.* 183, 669-674.
47. Lee, S.Y., A. Reichlin, A. Santana, K.A. Sokol, M.C. Nussenzweig, and Y. Choi. (1997) *Immunity* 7, 703-713.
48. Li Y et al (1998) *Mol Cell Biol.* 18, 1601-10.
49. Lin, A., A. Minden, H. Martinetto, F.X. Claret, C. Lange-Carter, F. Mercurio, G.L. Johnson, and M. Karin. (1995) *Science* 268, 286-290.
- 30 50. Liu, Z.-G., Hsu, H. Goeddel D.V., and Karin M.. 1996. *Cell* 87, 565-576
51. Mashima, T. et al. (1995) *Biochem. Biophys. Res. Commun.* 209, 907-915.

52. McDonald, P. P., Cassatella, M. A., Bald, A., Maggi, E., Romagnani, S., Gruss, H. J., and Pizzolo, G. (1995). *Eur J Immunol* 25, 2870-6.
53. Mercurio F and Manning AM (1999a) *Curr Opin Cell Biol.* 1999 11,226-32
54. Mercurio F et al (1999b) *Mol Cell Biol.* 19, 1526-38.
- 5 55. Messing et al., Third Cleveland Symposium on Macromolecules and Recombinant DNA, Ed. A. Walton, Elsevier, Amsterdam (1981)
56. Minden, A., Lin A., McMahon M., Lange-Carter C., Derijard B., Davis R.J., Johnson, G.L. and Karin M. 1994. *Science* 266, 1719-1723.
57. Milligan, C.E. et al. (1995) *Neuron* 15, 385-393.
- 10 58. Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C., and Kieff, E. (1995). *Cell* 80, 389-399.
59. Muranishi, S. et al. (1991) *Pharm. Research* 8, 649.
60. Nagata, S. and Golstein, P. (1995) *Science* 267, 1449-1456.
61. Nakano H (1996) *J Biol Chem.* 271, 14661-4.
- 15 62. Park, Y.C. (1999) *Nature.* 398, 533-8
63. Reinhard C., Shmoon, B. Shyamala, V. and Williams. L.T. 1997. *EMBO J.* 16, 1080-1092
64. Régnier CH (1995) *J Biol Chem.* 270, 25715-21.
65. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M (1997) *Cell* 90, 373-383
- 20 66. Rensing-Ehl, A., Hess, S., Ziegler-Heitbrock, H. W. L., Riethmüller, G., and Engelmann, H. (1995). *J. Inflamm.* 45, 161-174.
67. Rothe, M., Pan, M-G, Henzel, W. J., Ayres, T. M., and Goeddel, D. V. (1995b). *Cell* 83, 1243-1252.
- 25 68. Rothe, M., Sarma, V., Dixit, V. M., and Goeddel, D. V. (1995a). *Science* 269, 1424-1427.
69. Rothe, M., Wong, S. C., Henzel, W. J., and Goeddel, D. V. (1994). *Cell* 78, 681-692.
70. Rothe, M. et al. (1996) *Proc. Natl. Acad. Sci. U.S.A.* 93, 8241-8246.
- 30 71. Rothwarf DM et al (1998) *Nature.* 395,297-300.
72. Roy, N., Q.L. Deveraux, R. Takahashi, G.S. Salvesen, and J.C. Reed. (1997). *EMBO J.* 16, 6914-6925.
73. Ruzicka et al., (1993) *Science* 260, 487.

74. Sambrook et al. (1989) Molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
75. Sano et al., (1992) Science 258, 120.
76. Sano et al., (1991) Biotechniques 9, 1378.
- 5 77. Schreiber, E., Matthias, P., Muller, M.M. and Schaffner, W. (1989), Nuc. Acids Res. 17:6419.
78. Schulz et al., G.E., Principles of Protein Structure, Springer-Verlag, New York, N.Y. 1798.
79. Sleath, P.R. et al. (1990) J. Biol. Chem. 265,14526-14528.
- 10 80. Shi, C.-S. and J.H. Kehrl. (1997) *J. Biol. Chem.* 272, 32102-32107.
81. Smith, C. A., Farrah, T., and Goodwin, R. G. (1994). Cell 76, 959-962.
82. Song, H.Y., C.H. Régnier, C.J. Kirschning, D.V. Goeddel, and M. Rothe. (1997). *Proc. Natl. Acad. Sci.* 9, 9792-9796
83. Stanger, B.Z. et al. (1995) Cell 81, 513-523.
- 15 84. Su, B., E. Jacinto, M. Hibi, T. Kallunki, M. Karin, and Y. Ben-Neriah. (1994) *Cell* 77, 727-736
85. Thornberry, N.A. et al. (1992) Nature 356,768-774.
86. Thornberry, N.A. et al. (1994) Biochemistry 33, 3934-3940.
87. Vandenabeele, P., Declercq, W., Beyaert, R., and Fiers, W. (1995). Trends Cell Biol. 5, 392-400.
- 20 88. Varfolomeev, E. E., Boldin, M. P., Goncharov, T. M., and Wallach, D. (1996). J. Exp. Med. 183, 1271-5.
89. Vassalli, P. (1992) Ann. Rev. Immunol. 10, 411-452.
90. Veira et al., (1987) Meth. Enzymol. 153, 3.
- 25 91. Wallach, D. (1996) Eur. Cytokine Net. 7, 713-724.
92. Wang, L. et al. (1994) Cell 78, 739-750.
93. Wilks, A.F. et al. (1989) Proc. Natl. Acad. Sci. USA, 86:1603-1607.
94. Yamaoka S et al. (1998) Cell. 93, 1231-40.
95. Yeh, W.-C., A. Shahinian, D. Speiser, J. Kraunus, F. Billia, A. Wakeham, J.L. de la Pompa, D. Ferrick, B. Hum, N. Iscove, P. Ohashi, M. Rothe, D.V. Goeddel, and T.W. Mak. (1997) *Immunity* 7, 715-725
- 30 96. Zaccharia, S. et al. (1991) Eur. J. Pharmacol. 203, 353-357.
97. Zhao, J.J. and Pick, L. (1993) Nature 365: 448-451.

CLAIMS

1. A DNA sequence encoding a protein capable of binding to TRAF selected from the group consisting of:
 - 5 (a) a cDNA sequence of the herein designated IREN comprising the nucleotide sequence depicted in Fig. 3;
 - (b) a cDNA sequence of the herein designated IREN-10B comprising the nucleotide sequence depicted in Fig. 4;
 - (c) a cDNA sequence of the herein designated IREN-E comprising the
10 nucleotide sequence depicted in Fig. 5;
 - (d) a fragment of a sequence (a)-(c) which encodes a biologically active protein capable of binding to at least the 225-501 amino acid sequence of TRAF2;
 - (e) a DNA sequence capable of hybridization to a sequence of (a)-(d) under moderately stringent conditions and which encodes a biologically active protein capable
15 of binding to at least the 225-501 amino acid sequence of TRAF2; and
 - (f) a DNA sequence which is degenerate as a result of the genetic code to the DNA sequences defined in (a)-(e) and which encodes a biologically active protein capable of binding to at least the 225-501 amino acid sequence of TRAF2.
2. A DNA sequence according to claim 1, selected from the cDNA sequences
20 herein designated IREN and IREN-10B and IREN-E.
3. A DNA sequence according to any one of claim 1 or 2, encoding a protein that modulates NF- κ B activity.
4. A DNA sequence according to claim 3, selected from the sequences contained in the herein-designated cDNA IREN.
- 25 5. A DNA sequence according to any one of the preceding claims, comprising the DNA sequence encoding the protein IREN (as herein defined).
6. A DNA sequence encoding the protein IREN, isoforms, fragments or analogs thereof, said IREN, isoforms, fragments or analogs thereof being capable of binding to TRAF2 and of modulating the activity of NF- κ B.
- 30 7. A DNA sequence according to claim 6, selected from the group consisting of:
 - a) a cDNA sequence derived from the coding region of a native IREN protein;

b) DNA sequences capable of hybridization to a sequence of (a) under moderately stringent conditions and which encode a biologically active IREN; and

c) DNA sequences which are degenerate as a result of the genetic code to the sequences defined in (a) and (b) and which encode a biologically active IREN protein.

8. A DNA sequence according to claim 6 or 7 comprising at least part of the sequence depicted in Fig. 6 and encoding at least one active IREN protein, isoform, analog or fragment.

9. A DNA sequence according to claim 8 encoding a IREN protein, isoform, analog or fragment having at least part of the amino acid sequence depicted in Fig. 6.

10. A vector comprising a DNA sequence according to any one of claims 1-9.

11. A vector according to claim 10 capable of being expressed in a eukaryotic host cell.

12. A vector according to claim 10 capable of being expressed in a prokaryotic host cell.

13. Transformed eukaryotic or prokaryotic host cells containing a vector according to any one of claims 10-12.

14. An IREN protein, isoforms, fragments, analogs and derivatives thereof, encoded by a DNA sequence according to any one of claims 1-9, said protein, isoforms, fragments, analogs and derivatives thereof being capable of binding to at least the portion of the TRAF2 protein between amino acids 225-501 of TRAF2.

15. A protein according to claim 14 being the protein encoded by herein-designated clone 10B.

16. A protein, isoforms, fragments, analogs and derivatives thereof according to claim 14 being the protein IREN, isoforms, analogs, fragments and derivatives thereof encoded by the DNA sequence according to any one of claims 1-9.

17. A protein IREN, isoforms, analogs, fragments and derivatives thereof according to claim 16, wherein said protein, isoforms, fragments and derivatives have at least part of the amino acid sequence depicted in Fig. 6.

18. A method for producing a protein, isoform, fragment, analog or derivative thereof according to any one of claims 14-16, which comprises growing a transformed host cell according to claim 16 under conditions suitable for the expression of said protein, isoform, fragment, analog or derivative thereof, effecting post-translational

19. Antibodies or active fragments or derivatives thereof, specific for the IREN
5 protein, isoform, analog, fragment or derivative thereof according to claim 14 or 15; or
specific for the protein IREN, isoform, analog, fragment or derivative thereof according
to claim 16 or 17.

20. A method for the modulation or mediation in cells of the activity of NF- κ B or any other intracellular signaling activity modulated or mediated by TRAF2 or by other molecules to which a protein, isoform, analog, fragment or derivative thereof according to any one of claims 14 to 17 binds, said method comprising treating said cells by introducing into said cells one or more of said protein, isoform, analog, fragment or derivative thereof in a form suitable for intracellular introduction thereof, or introducing into said cells a DNA sequence encoding said one or more protein, isoform, analog, fragment or derivative thereof in the form of a suitable vector carrying said sequence, said vector being capable of effecting the insertion of said sequence into said cells in a way that said sequence is expressed in said cells.

21. A method according to claim 20, wherein said treating of cells comprises
 , introducing into said cells a DNA sequence encoding said protein, isoform, fragment,
 20 analog or derivative in the form of a suitable vector carrying said sequence, said vector
 being capable of effecting the insertion of said sequence into said cells in a way that said
 sequence is expressed in said cells.

22. A method according to claim 20 or 21 wherein said treating of said cells is by transfection of said cells with a recombinant animal virus vector comprising the steps of:

(a) constructing a recombinant animal virus vector carrying a sequence encoding a viral surface protein (ligand) that is capable of binding to a specific cell surface receptor on the surface of said cells to be treated and a second sequence encoding a protein selected from the said protein, isoforms, analogs, fragments and derivatives according to any one of claims 14 to 17, that when expressed in said cells is capable of modulating/mediating the activity of NF- κ B or any other intracellular signaling activity modulated/mediated by TRAF2 or other said molecules; and

28. A method according to any one of claims 20 to 27 wherein said protein is IREN or at least one of the IREN isoforms, analogs, fragments and derivatives thereof.

29. A pharmaceutical composition for the modulation of the TRAF2 modulated/mediated effect on cells comprising, as active ingredient at least one IREN protein, according to any one of claims 14 to 17, its biologically active fragments, analogs, derivatives or mixtures thereof.

30. A pharmaceutical composition for modulating the TRAF2 modulated/mediated effect on cells comprising, as active ingredient, a recombinant animal virus vector encoding a protein capable of binding a cell surface receptor and encoding at least one IREN protein, isoform, active fragments or analogs, according to any one of claims 14 to 17.

31. A pharmaceutical composition for modulating the TRAF2 modulated/mediated effect on cells comprising as active ingredient, an oligonucleotide sequence encoding an anti-sense sequence of the IREN protein mRNA sequence according to any one of claims 1 to 8.

32. A pharmaceutical composition for the prevention or treatment of a pathological condition associated with NF- κ B induction or with any other activity mediated by TRAF2 or by other molecules to which a protein according to any one of claims 14 to 17 binds, said composition comprising an effective amount of a protein encoded by IREN-10B or a DNA molecule coding therefor, or a molecule capable of disrupting the interaction of said protein encoded by IREN-10B with TRAF2 or any other molecule to which a protein encoded by IREN-10B binds.

33. A pharmaceutical composition for the prevention or treatment of a pathological condition associated with NF- κ B induction or with any other activity mediated by TRAF2 or by other molecules to which a protein according to any one of claims 14 to 17 binds, said composition comprising an effective amount of a protein IREN, isoform, fragment, analog or derivative thereof, or a DNA molecule coding therefor, or a molecule capable of disrupting the interaction of said protein IREN, isoform, fragment, analog or derivative thereof with TRAF2 or any other molecule to which said protein IREN, isoform, fragment, analog or derivative binds.

34. A pharmaceutical composition for the prevention or treatment of a pathological condition associated with NF- κ B induction or with any other activity

SECRET

35. A pharmaceutical composition for the prevention or treatment of a
5 pathological condition associated with NF- κ B induction or with any other activity
mediated by TRAF2 or by other molecules to which a protein encoded by IREN-10B
according to claim 15 binds, said composition comprising an effective amount of a
protein encoded by IREN 10B or a DNA molecule coding therefor, or a molecule
capable of disrupting the interaction of said protein encoded by IREN 10B with TRAF2
10 or any other molecule to which said protein encoded by IREN 10B binds.

36. A pharmaceutical composition for the prevention or treatment of a pathological condition associated with NF- κ B induction or with any other activity mediated by TRAF2 or by other molecules to which a protein IREN, isoform, fragment, analog or derivative according to claim 16 or 17 binds, said composition comprising an effective amount of a protein IREN, isoform, fragment, analog or derivative thereof, or a DNA molecule coding therefor, or a molecule capable of disrupting the interaction of said protein IREN, isoform, fragment, analog or derivative thereof with TRAF2 or any other molecule to which said protein IREN, isoform, fragment, analog or derivative binds.

37. A method for the prevention or treatment of a pathological condition associated with NF- κ B induction or with any other activity mediated by TRAF2 or by other molecules to which a protein according to any one of claims 14 to 17 binds, said method comprising administering to a patient in need an effective amount of a protein or isoform, fragment, analog and derivative thereof or a mixture of any thereof according to any one of claims 14 to 17, or a DNA molecule coding therefor, or a molecule capable of disrupting the interaction of said protein or isoform, fragment, analog and derivative thereof or a mixture of any thereof according to any one of claims 14 to 17 with TRAF2 or any other molecule to which said protein or isoform, fragment, analog and derivative thereof or a mixture of any thereof according to any one of claims 14 to 17 binds.

38. A method according to claim 37 wherein said protein is encoded by IREN.

39. A method according to claim 37, wherein said protein is IREN.

40. A method for screening of a ligand capable of binding to a protein according to any one of claims 14 to 17 comprising contacting an affinity chromatography matrix to which said protein is attached with a cell extract whereby the ligand is bound to said matrix, and eluting, isolating and analyzing said ligand.

41. A method for screening of a DNA sequence coding for a ligand capable of binding to a protein according to any one of claims 14 to 17 comprising applying the yeast two-hybrid procedure in which a sequence encoding said protein is carried by one hybrid vector and sequences from a cDNA or genomic DNA library are carried by the second hybrid vector, transforming yeast host cells with said vectors, isolating the positively transformed cells, and extracting said second hybrid vector to obtain a sequence encoding said ligand.

42. A method for identifying and producing a ligand capable of modulating the cellular activity modulated/mediated by TRAF2 comprising:

15 a) Screening for a ligand capable of binding to a polypeptide comprising at least a portion of TRAF2 having the amino acid residues 225-501 of TRAF2;

b) Identifying and characterizing a ligand, other than TRAF2 or portions of a receptor of the TNF/NGF receptor family, found by said screening step to be capable of said binding; and

c) Producing said ligand in substantially isolated and purified form.

20 43. A method for identifying and producing a ligand capable of modulating the cellular activity modulated or mediated by a protein according to any one of claims 17-20 comprising :

a) Screening for a ligand capable of binding to a polypeptide comprising at least a portion of the sequence IREN depicted in Fig. 6;

25 b) Identifying and characterizing a ligand, other than TRAF2 or portions
of a receptor of the TNF/NGF receptor family, found by said screening step to be
capable of said binding; and

c) Producing said ligand in substantially isolated and purified form.

44. A method for identifying and producing a ligand capable of modulating the
30 cellular activity modulated/mediated by the protein IREN comprising:

a) Screening for a ligand capable of binding to at least a portion of the IREN sequence depicted in Fig. 6;

ABSTRACT

5

There are provided DNA sequences encoding TRAF binding proteins, proteins encoded thereby, and their use in the treatment or prevention of pathological conditions associated with NF- κ B induction, or an activity mediated by a TRAF.

1/25




Figure 1

2/25




Figure 2

3/25

GGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCTG
CGGATGTACCCATACGATGTTCCAGATACGCTGAATTTTCGAGGCCACGAAG
GCCGGCGGCGCGGCGCAGGCACCGGCCCGGGGAGAGGCACC

Figure 3A

4/25

ATG AGC GGA TCA CAG AAC AAT GAC AAA AGA CAA TTT CTG CTG GAG CGA CTG CTG GAT GCA
 61
 GTG AAA CAG TGC CAG ATC CGC TTT GGA GGG AGA AAG GAG ATT GCC TCG GAT TCC GAC AGC
 121
 AGG GTC ACC TGT CTG TGT GCC CAG TTT GAA GCC GTC CTG CAG CAT GGC TTG AAG AGG AGT
 181
 CGA GGA TTG GCA CTC ACA GCG GCA GCG ATC AAG CAG GCA GCG GGC TTT GCC AGC AAA ACC
 241
 GAA ACA GAG CCC GTG TTC TGG TAC TAC GTG AAG GAG GTC CTC AAC AAG CAC GAG CTG CAG
 301
 CGC TTC TAC TCC CTG CGC CAC ATC GCC TCA GAC GTG GGC CGG GGT CGC GCC TGG CTG CGC
 361
 TGT GCC CTC AAC GAA CAC TCC CTG GAG CGC TAC CTG CAC ATG CTC CTG GCC GAC CGC TGC
 421
 AGG CTG AGC ACT TTT TAT GAA GAC TGG TCT TTT GTG ATG GAT GAA GAA AGG TCC AGT ATG
 481
 CTT CCT ACC ATG GCA GCA GGT CTG AAC TCC ATA CTC TTT GCG ATT AAC ATC GAC AAC AAG
 541
 GAT TTG AAC GGG CAG AGT AAG TTT GCT CCC ACC GTT TCA GAC CTC TTA AAG GAG TCA ACG
 601
 CAG AAC GTG ACC TCC TTG CTG AAG GAG TCC ACG CAA GGA GTG AGC AGC CTG TTC AGG GAG
 661
 ATC ACA GCC TCC TCT GCC GTC TCC ATC CTC ATC AAA CCT GAA CAG GAG ACC GAC CCC TTG
 721
 CCT GTC GTG TCC AGG AAT GTC AGT GCT GAT GCC AAA TGC AAA AAG GAG CGG AAG AAG AAA
 781
 AAG AAA GTG ACC AAC ATA ATC TCA TTT GAT GAT GAG GAA GAT GAG CAG AAC TCT GGG GAC
 841
 GTG TTT AAA AAG ACA CCT GGG GCA GGG GAG AGC TCA GAG GAC AAC TCC GAC CGC TCC TCT
 901
 GTC AAT ATC ATG TCC GCC TTT GAA AGC CCC TTC GGG CCT AAC TCC AAT GGA AGT CAG AGC
 961
 AGC AAC TCA TGG AAA ATT GAT TCC CTG TCT TTG AAC GGG GAG TTT GGG TAC CAG AAG CTT
 1021
 GAT GTG AAA AGC ATC GAT GAT GAA GAT GTG GAT GAA AAC GAA GAT GAC GTG TAT GGA AAC
 1081
 TCA TCA GGA AGG AAG CAC AGG GGC CAC TCG GAG TCG CCC GAG AAG CCA CTG GAA GGG AAC
 1141
 ACC TGC CTC TCC CAG ATG CAC AGC TGG GCT CCG CTG AAG GTG CTG CAC AAT GAC TCC GAC
 1201
 ATC CTC TTC CCT GTC AGT GGC GTG GGC TCC TAC AGC CCA GCA GAT GCC CCC CTC GGA AGC
 1261
 CTG GAG AAC GGG ACA GGA CCA GAG GAC CAC GTT CTC CCG GAT CCT GGA CTT CGG TAC AGT
 1321
 GTG GAA GCC AGC TCT CCA GGC CAC GGA AGT CCT CTG AGC AGC CTG TTA CCT TCT GCC TCA
 1381
 GTG CCA GAG TCC ATG ACA ATT AGT GAA CTG CGC CAG GCC ACT GTG GCC ATG ATG AAC AGG
 1441
 AAG GAT GAG CTG GAG GAG GAG AAC AGA TCA CTG CGA AAC CTG CTC GAC GGT GAG ATG GAG
 1501/501
 CAC TCA GCC GCG CTC CGG CAA GAG GTG GAC ACC TTG AAA AGG AAG GTG GCT GAA CAG GAG
 1561
 GAG CGG CAG GGC ATG AAG GTC CAG GCG CTG GCC AGC TAT CTT TGC TAT TTT GTG AGG AGA
 1621
 TTC TAA CCC CAC GTG AGA ACC ATG TGG TGG AGA AAT GGA GGG AGA GAG AAA TCC AAC AGT
 1681
 TCC TGA TAG TCT CAT TTG AGC TCC TGG ATC CAG TCT TTC CTG AAG CTG TGT TTC CTC TGG
 1741
 ACT TTT CAT GTA TGT GAG CCA ATA AAT TGC TTT CAT TCC TTG

Figure 3B

5/25

ATG	AGC	GGA	TCA	CAG	AAC	AAT	GAC	AAA	AGA	CAA	TTT	CTG	CTG	GAG	CGA	CTG	CTG	GAT	GCA
61										91									
GTG	AAA	CAG	TGC	CAG	ATC	CGC	TTT	GGA	GGG	AGA	AAG	GAG	ATT	GCC	TCG	GAT	TCC	GAC	AGC
121										151									
AGG	GTC	ACC	TGT	CTG	TGT	GCC	CAG	TTT	GAA	GCC	GTC	CTG	CAG	CAT	GGC	TTG	AAG	AGG	AGT
181										211									
CGA	GGA	TTG	GCA	CTC	ACA	GCG	GCA	GCG	ATC	AAG	CAG	GCA	GCG	GGC	TTT	GCC	AGC	AAA	ACC
241										271									
GAA	ACA	GAG	CCC	GTG	TTC	TGG	TAC	TAC	GTG	AAG	GAG	GTC	CTC	AAC	AAG	CAC	GAG	CTG	CAG
301										331									
CGC	TTC	TAC	TCC	CTG	CGC	CAC	ATC	GCC	TCA	GAC	GTG	GGC	CGG	GGT	CGC	GCC	TGG	CTG	CGC
361										391									
TGT	GCC	CTC	AAC	GAA	CAC	TCC	CTG	GAG	CGC	TAC	CTG	CAC	ATG	CTC	CTG	GCC	GAC	CGC	TGC
421										451									
AGG	CTG	AGC	ACT	TTT	TAT	GAA	GAC	TGG	TCT	TTT	GTG	ATG	GAT	GAA	GAA	AGG	TCC	AGT	ATG
481										511									
CTT	CCT	ACC	ATG	GCA	GCA	GGT	CTG	AAC	TCC	ATA	CTC	TTT	GCG	ATT	AAC	ATC	GAC	AAC	AAG
541										571									
GAT	TTG	AAC	GGG	CAG	AGT	AAG	TTT	GCT	CCC	ACC	GTT	TCA	GAC	CTC	TTA	AAG	GAG	TCA	ACG
601										631									
CAG	AAC	GTG	ACC	TCC	TTG	CTG	AAG	GAG	TCC	ACG	CAA	GGA	GTG	AGC	AGC	CTG	TTC	AGG	GAG
661										691									
ATC	ACA	GCC	TCC	TCT	GCC	GTC	TCC	ATC	CTC	ATC	AAA	CCT	GAA	CAG	GAG	ACC	GAC	CCC	TTG
721										751									
CCT	GTC	GTG	TCC	AGG	AAT	GTC	AGT	GCT	GAT	GCC	AAA	TGC	AAA	AAG	GAG	CGG	AAG	AAG	AAA
781										811									
AAG	AAA	GTG	ACC	AAC	ATA	ATC	TCA	TTT	GAT	GAT	GAG	GAA	GAT	GAG	CAG	AAC	TCT	GGG	GAC
841										871									
GTG	TTT	AAA	AAG	ACA	CCT	GGG	GCA	GGG	GAG	AGC	TCA	GAG	GAC	AAC	TCC	GAC	CGC	TCC	TCT
901										931									
GTC	AAT	ATC	ATG	TCC	GCC	TTT	GAA	AGC	CCC	TTT	GGG	CCT	AAC	TCC	AAT	GGA	AGT	CAG	AGC
961										991									
AGC	AAC	TCA	TGG	AAA	ATT	GAT	TCC	CTG	TCT	TTG	AAC	GGG	GAG	TTT	GGG	TAC	CAG	AAG	CTT
1021										1051									
GAT	GTG	AAA	AGC	ATC	GAT	GAT	GAA	GAT	GTG	GAT	GAA	AAC	GAA	GAT	GAC	GTG	TAT	GGA	AAC
1081										1111									
TCA	TCA	GGA	AGG	AAG	CAC	AGG	GGC	CAC	TCG	GAG	TCG	CCC	GAG	AAG	CCA	CTG	GAA	GGG	AAC
1141										1171									
ACC	TGC	CTC	TCC	CAG	ATG	CAC	AGC	TGG	GCT	CCG	CTG	AAG	GTG	CTG	CAC	AAT	GAC	TCC	GAC
1201										1231									
ATC	CTC	TTC	CCT	GTC	AGT	GGC	GTG	GGC	TCC	TAC	AGC	CCA	GCA	GAT	GCC	CCC	CTC	GGA	AGC
1261										1291									
CTG	GAG	AAC	GGG	ACA	GGA	CCA	GAG	GAC	CAC	GTT	CTC	CCG	GAT	CCT	GGA	CTT	CGG	TAC	AGT
1321										1351									
GTG	GAA	GCC	AGC	TCT	CCA	GGC	CAC	GGA	AGT	CCT	CTG	AGC	AGC	CTG	TTA	CCT	TCT	GCC	TCA
1381										1411									
GTG	CCA	GAG	TCC	ATG	ACA	ATT	AGT	GAA	CTG	CGC	CAG	GCC	ACT	GTG	GCC	ATG	ATG	AAC	AGG
1441										1471									
AAG	GAT	GAG	CTG	GAG	GAG	GAG	AAC	AGA	TCA	CTG	CGA	AAC	CTG	CTC	GAC	GGT	GAG	ATG	GAG
1501										1531									
CAC	TCA	GCC	GCG	CTC	CGG	CAA	GAG	GTG	GAC	ACC	TTG	AAA	AGG	AAG	GTG	GCT	GAA	CAG	GAG
1561										1591									
GAG	CGG	CAG	GGC	ATG	AAG	GTC	CAG	GCG	CTG	GCC	AGA	GAG	AAC	GAG	GTG	CTC	AAA	GTC	CAA
1621										1651									
CTG	AAG	AAA	TAT	GTA	GGA	GCT	GTC	CAG	ATG	CTG	AAA	AGA	GAA	GGT	CAA	ACA	GCT	GAA	GTG
1681										1711									
CCA	AAT	CTT	TGG	AGT	GTT	GAT	GGA	GAA	GTT	ACA	GTA	GCT	GAA	CAG	AAG	CCG	GGA	GAA	ATT
1741										1771									
GCT	GAA	GAA	CTC	GCA	AGC	TCC	TAC	GAA	AGA	AAG	CTC	ATC	GAG	GTG	GCA	GAG	ATG	CAT	GGC
1801										1831									
GAG	CTG	ATT	GAG	TTC	AAC	GAG	CGC	CTG	CAC	AGG	GCC	CTG	GTA	GCC	AAG	GAA	GCC	CTC	GTG

Figure 4

6/25

1861	TCC CAG ATG AGG CAG GAG CTC ATC GAT CTC	1891	CGG GGA CCG GTG CCT GGA GAT TTG AGT CAA
1921	ACG TCC GAA GAC CAG AGT TTG TCG GAT TTT	1951	GAA ATA TCA AAC CCG GCG CTG ATC AAC GTC
1981	TGG ATC CCC TCA GTG TTT CTC CGG GGC AAA	2011	GCA GCA AAT GCA TTC CAC GTG TAT CAG GTC
2041	TAC ATC CGG ATA AAA GAC GAT GAA TGG AAT	2071	ATT TAT CGC CGG TAT ACA GAG TTC AGG AGT
2101	TTG CAC CAC AAG TTA CAA AAC AAG TAC CCT	2131	CAA GTG AGG GCC TAC AAC TTC CCA CCC AAA
2161	AAG GCC ATT GGA AAC AAG GAT GCC AAG TTT	2191	GTG GAG GAA CGG AGA AAG CAG CTC CAG AAT
2221	TAC CTG CGC AGC GTC ATG AAC AAA GTC ATC	2251	CAG ATG GTC CCC GAG TTC GCT GCC AGC CCC
2281	AAG AAG GAG ACC CTC ATC CAG CTG ATG CCC	2311	TTC TTC GTC GAC ATC ACC CCG CCC GGA GAG
2341	CCT GTG AAC AGC CGG CCC AAA GCA GCT TCC	2371	CGC TTT CCC AAA CTG TCC CGG GGT CAG CCC
2401	CGG GAG ACC CGC AAC GTG GAG CCC CAG AGC	2431	GGT GAC CTC TGA CCT CGA CAA AAC CGC AGC
2461	CAC GGG CCC TGT GCG TGG CAC CAG CTG CGT	2491	CCA CCC CAG CCA CTG CCG CTG GCC CCT CAC
2521	CTC AGC GTG ACA ACC ACG TCC CAC TGG TGA	2551	TCC TGA GAG CAC ACG ATT CCC AAC AGT TAC
2581	ACA ACA CCC CGA TTA AAC TAA TCA GTC TTC	2611	GAG CCG CAT GAT ACC GTG ACC CGA GAG ACC
2641	AAG GCA GCA CCT CGC TGG AGA GAC TGG GAC	2671	ACA CAG TCC TTC TGC TTC TGG GGT CTA CCC
2701	TGG GCT GCA AGG GCT GTT CCT CCA CCT TCC	2731	TAT AGT TCA GGG CTG GCA GGA GGG TGG GCA
2761	CCA GGT CAG GCT GGG TGC GCC ATG GTT GAG	2791	AGG CAA AGG TGA TCC CCT ATA TAG GAA GGT
2821	TCA TGC AGA GCC AGC CTC TCC ACT CTT TCC	2851	CAT GTG GGG ACT AGA ATG ACT ATT AGC CTC
2881	TTC CTT TGC TTT TTA AGG TTA TTA CCT GGC	2911	CTA ACC TAG GGA TGG CTG GCT GTG GGG GGG
2941	GGG GGT GGG CAT GGT TCC TTT CAC TGC ATT	2971	TTC CAC CAA CAG TCA TTA GAC ACC TGG CAC
3001	TGT CAC AGC TCA CTT TTC CAG AGG GAT ATT	3031	CCT GTG GCT TTG GCA AGG AGC CAT TAG TGA
3061	TGT GCA ACT TGA GTT CAG AGA ACT TCC CCT	3091	ACC TCC CCC ATG GCT GGC TTC AGG AAG GAC
3121	CAG TGC CCT CCA TAG CCT G		

Figure 4 (cont.)

7/25

ATG	AGC	GGA	TCA	CAG	AAC	AAT	GAC	AAA	AGA	CAA	TTT	CTG	CTG	GAG	CGA	CTG	CTG	GAT	GCA
61										91									
GTG	AAA	CAG	TGC	CAG	ATC	CGC	TTT	GGA	GGG	AGA	AAG	GAG	ATT	GCC	TCG	GAT	TCC	GAC	AGC
121										151									
AGG	GTC	ACC	TGT	CTG	TGT	GCC	CAG	TTT	GAA	GCC	GTC	CTG	CAG	CAT	GGC	TTG	AAG	AGG	AGT
181										211									
CGA	GGA	TTG	GCA	CTC	ACA	GCG	GCA	GCG	ATC	AAG	CAG	GCA	GCG	GGC	TTT	GCC	AGC	AAA	ACC
241										271									
GAA	ACA	GAG	CCC	GTG	TTC	TGG	TAC	TAC	GTG	AAG	GAG	GTC	CTC	AAC	AAG	CAC	GAG	CTG	CAG
301										331									
CGC	TTT	TAC	TCC	CTG	CGC	CAC	ATC	GCC	TCA	GAC	GTG	GGC	CGG	GGT	CGC	GCC	TGG	CTG	CGC
361										391									
TGT	GCC	CTC	AAC	GAA	CAC	TCC	CTG	GAG	CGC	TAC	CTG	CAC	ATG	CTC	CTG	GCC	GAC	CGC	TGC
421										451									
AGG	CTG	AGC	ACT	TTT	TAT	GAA	GAC	TGG	TCT	TTT	GTG	ATG	GAT	GAA	GAA	AGG	TCC	AGT	ATG
481										511									
CTT	CCT	ACC	ATG	GCA	GCA	GGT	CTG	AAC	TCC	ATA	CTC	TTT	GCG	ATT	AAC	ATC	GAC	AAC	AAG
541										571									
GAT	TTG	AAC	GGG	CAG	AGT	AAG	TTT	GCT	CCC	ACC	GTT	TCA	GAC	CTC	TTA	AAG	GAG	TCA	ACG
601										631									
CAG	AAC	GTG	ACC	TCC	TTG	CTG	AAG	GAG	TCC	ACG	CAA	GGA	GTG	AGC	AGC	CTG	TTC	AGG	GAG
661										691									
ATC	ACA	GCC	TCC	TCT	GCC	GTC	TCC	ATC	CTC	ATC	AAA	CCT	GAA	CAG	GAG	ACC	GAC	CCC	TTG
721										751									
CCT	GTC	GTG	TCC	AGG	AAT	GTC	AGT	GCT	GAT	GCC	AAA	TGC	AAA	AAG	GAG	CGG	AAG	AAG	AAA
781										811									
AAG	AAA	GTG	ACC	AAC	ATA	ATC	TCA	TTT	GAT	GAT	GAG	GAA	GAT	GAG	CAG	AAC	TCT	GGG	GAC
841										871									
GTG	TTT	AAA	AAG	ACA	CCT	GGG	GCA	GGG	GAG	AGC	TCA	GAG	GAC	AAC	TCC	GAC	CGC	TCC	TCT
901										931									
GTC	AAT	ATC	ATG	TCC	GCC	TTT	GAA	AGC	CCC	TTT	GGG	CCT	AAC	TCC	AAT	GGA	AGT	CAG	AGC
961										991									
AGC	AAC	TCA	TGG	AAA	ATT	GAT	TCC	CTG	TCT	TTG	AAC	GGG	GAG	TTT	GGG	TAC	CAG	AAG	CTT
1021										1051									
GAT	GTG	AAA	AGC	ATC	GAT	GAT	GAA	GAT	GTG	GAT	GAA	AAC	GAA	GAT	GAC	GTG	TAT	GGA	AAC
1081										1111									
TCA	TCA	GGA	AGG	AAG	CAC	AGG	GGC	CAC	TCG	GAG	TCG	CCC	GAG	AAG	CCA	CTG	GAA	GGG	AAC
1141										1171									
ACC	TGC	CTC	TCC	CAG	ATG	CAC	AGC	TGG	GCT	CCG	CTG	AAG	GTG	CTG	CAC	AAT	GAC	TCC	GAC
1201										1231									
ATC	CTC	TTC	CCT	GTC	AGT	GGC	GTG	GGC	TCC	TAC	AGC	CCA	GCA	GAT	GCC	CCC	CTC	GGA	AGC
1261										1291									
CTG	GAG	AAC	GGG	ACA	GGA	CCA	GAG	GAC	CAC	GTT	CTC	CCG	GAT	CCT	GGA	CTT	CGG	TAC	AGT
1321										1351									
GTG	GAA	GCC	AGC	TCT	CCA	GGC	CAC	GGA	AGT	CCT	CTG	AGC	AGC	CTG	TTA	CCT	TCT	GCC	TCA
1381										1411									
GTG	CCA	GAG	TCC	ATG	ACA	ATT	AGT	GAA	CTG	CGC	CAG	GCC	ACT	GTG	GCC	ATG	ATG	AAC	AGG
1441										1471									
AAG	GAT	GAG	CTG	GAG	GAG	GAG	AAC	AGA	TCA	CTG	CGA	AAC	CTG	CTC	GAC	GGT	GAG	ATG	GAG
1501										1531									
CAC	TCA	GCC	GCG	CTC	CGG	CAA	GAG	GTG	GAC	ACC	TTG	AAA	AGG	AAG	GTG	GCT	GAA	CAG	GAG
1561										1591									
GAG	CGG	CAG	GGC	ATG	AAG	GTC	CAG	GCG	CTG	GCC	AGA	GAG	AAC	GAG	GTG	CTC	AAA	GTC	CAA

Figure 5

8/25

1621	CTG AAG AAA TAT GTA GGA GCT GTC CAG ATG	1651	CTG AAA AGA GAA GGT CAA ACA GCT GAA GTG
1681	CCA AAT CTT TGG AGT GTT GAT GGA GAA GTT	1711	ACA GTA GCT GAA CAG AAG CCG GGA GAA ATT
1741	GCT GAA GAA CTC GCA AGC TCC TAC GAA AGA	1771	AAG CTC ATC GAG GTG GCA GAG ATG CAT GGC
1801	GAG CTG ATT GAG TTC AAC GAG CGC CTG CAC	1831	AGG GCC CTG GTA GCC AAG GAA GCC CTC GTG
1861	TCC CAG ATG AGG CAG GAG CTC ATC GAT CTC	1891	CGG GGA CCG GTG CCT GGA GAT TTG AGT CAA
1921	ACG TCC GAA GAC CAG AGT TTG TCG GAT TTT	1951	GAA ATA TCA AAC CGG GCG CTG ATC AAC GTC
1981	TGG ATC CCC TCA GTG TTT CTC CGG GGC AAA	2011	GCA GCA AAT GCA TTC CAC GTG TAT CAG GTC
2041	TAC ATC CGG ATA AAA GAC GAT GAA TGG AAT	2071	ATT TAT CGC CGG TAT ACA GAG TTC AGG AGT
2101	TTG CAC CAC AAG TTA CAA AAC AAG TAC CCT	2131	CAA GTG AGG GCC TAC AAC TTC CCA CCC AAA
2161	AAG GCC ATT GGA AAC AAG GAT GCC AAG TTT	2191	GTG GAG GAA CGG AGA AAG CAG CTC CAG AAT
2221	TAC CTG CGC AGC GTC ATG AAC AAA GTC ATC	2251	CAG ATG GTC CCC GAG TTC GCT GCC AGC CCC
2281	AAG AAG GAG ACC CTC ATC CAG CTG ATG CCC	2311	TTC TTC GTC GAC TGG ATC TCA CTT GTT TGG
2341	AAA TGG CCG CGA TAG TTC ACG TGA GGA GTT	2371	CTC ATC CTC TTA GCG GCA TCC CCA TGG CCC
2401	AGG GTG CAC GGG GGA ATT AGC CTC TCG CGG	2431	AGT CAT CAC GCA TCG ACT GAA TTC CCT GGT
2461	GAA AAC TGA GTT AGC CAG TTG TTC CTA AGA	2491	TAC TCC TGA TGC TGA GAG TGT GAG CAG GAG
2521	GCG CTG CCC CAT CCG CAA GTC AGT GTC CCC	2551	CAC CCC CTG CGG GGT CCA CAG CCC AGG CAT
2581	CTC CGG TCC AGT GTT TCC CAA ACA TTC GCG	2611	TGC CGA ATT GTA AAA AGT GCA CGT TAA TGC
2641	GAG CCT GTC GGT GTG ACA TGA ATC TCA GCC	2671	ATG CTG GTT GCC ATC AGT CAG CAC GGA GAG
2701	AGA AAC CTT TTG TGC CTA ATT AGC ACG CAG	2731	AAC AGA ACA CAG GGT TCG ATT TAT GGA CTT
2761	TTC AAA ACG AGA ATT TCA GTG GGA GAC TGT	2791	GGC AAA TGA CAC AGT GTT GAC ACT GGA ATT
2821	TTG ACT ACA TGT TGG TCT AGA GCG GCC GCC	2851	ACC GCG GTG GAG CTC CAA TTC GT

Figure 5 (cont.)

Figure 6

Figure 6

10/25

M R R C R F K R C L F A D L T A P E D P V N L D S P P S L G P T K D T K L Q T S
S L K A G A E H A A V G L K Q V V R E G N G N D S L L G E L L I D G L V K T V S
G L E Q L S V I L D M L N E G S V K E A I S G E G E K V N R S S E E K Q K A A Y
S D I F A K L A N R D N G S V I S K D G M Q E D R G V G G Y S E L M R A Y E E E
Q A A E L T N S E C E S Q T S L R K E E S S F V K N L S T S L L E E K L V V Q R
N V S A T E K D H R E I S Q S I N K Q S A S G D H T H Y G V L R E H V A G P K K
N K D V A T H V S L R L K N L K V K N S F N Y E R C N S P E P Q E S A R A N P L
D Q S L A E E G L S S F V F P S V S E E S Q N G L D P E A S A N A E E V L G I
K C D Q A P L R E T S A A T R E A T G D S W K E H S S A D S A T R A Q N Q W E E
R Q S H I V Q G R F M I P S E Q D N D N P K L D S Q D D H S S V S L E E M S I V
Q I R G K F R R Y Y L N T L I E A I V S F I D D E M I A V P V A L R E V L V A A
F R V L Q W F A L E P I V L T T K I F D G D V V S H L P L G P M R Q R L K D E E
L F T K A Y Y W H D T D S K A D C S K R P S K Y P S F L P H E M N E Q K R G E M
L G C R A Y S L M W M N D E S P K F K S N L S G E W P G D G S N L V G V E E L H
E G L S G V L R L S A K L S S L K D T S S S I N K A V S P S M R L D M Q G V A G

Figure 7

11/25

E	L	I	E	F	N	E	R	L	H	R	A	L	L	V	A
K	E	A	L	V	S	Q	M	R	Q	E	T	S	I	D	L
R	G	P	V	P	G	D	L	S	R	A	A	L	E	N	Q
S	L	S	F	F	E	I	S	N	K	A	D	S	I	A	V
W	I	P	V	V	F	L	R	G	K	D	L	L	N	W	F
H	V	Y	Y	Y	Y	I	R	I	K	N	H	I	E	K	N
I	N	R	P	P	T	E	F	R	S	V	F	N	H	P	L
Q	A	K	N	N	Q	V	R	A	Y	N	E	K	P	R	K
K	Q	I	G	E	K	D	A	K	F	V	F	E	K	V	R
K	M	L	Q	L	Y	L	R	S	V	M	N	N	P	T	I
I	Q	A	P	A	F	L	A	S	P	K	K	P	P	G	L
P	V	V	M	V	F	A	V	D	I	T	F	P	P	K	E
S	R	T	S	P	P	F	A	A	S	R	E	P	P	Q	S
G	D	L	Q	R	R	K	T	R	N	V	V	P	P		

Figure 7 (cont.)

12/25

M	S	G	S	Q	N	N	D	K	R	Q	F	L	L	E
R	L	L	I	A	V	K	Q	C	S	I	R	F	G	G
R	K	Q	A	E	D	D	S	D	H	R	V	T	C	L
C	A	S	K	L	V	V	L	Q	I	G	L	K	R	S
R	G	L	L	T	A	T	A	A	K	F	W	A	A	V
F	A	S	A	N	H	H	E	P	Y	R	F	Y	Y	S
A	V	M	R	S	S	S	L	R	Y	Q	A	W	W	L
D	L	N	D	E	R	R	S	L	Y	G	L	H	M	R
T	K	E	N	S	I	L	F	K	L	R	E	D	N	L
A	Q	G	G	Q	S	N	P	A	N	L	P	T	D	S
P	V	S	V	T	S	L	S	T	E	K	I	S	S	A
E	R	K	I	S	R	K	D	R	Q	A	V	C	E	K
D	N	E	A	E	E	S	N	G	D	I	R	S	D	L
	G	S	I	S	F	N	Q	S	N	V	D	K	E	S
	N	G	S	S	N	Y	E	W	P	S	G	P	S	S
	D	E	E	F	G			K	F	I	V	K	T	I
														N

Figure 8

13/25

S P P S L G P T K D T K L Q T S E K R S W H I Q K K I K
S L L G E L L I D G L V K T V S L E G L I V Y N A Q M Q W
G E K V N R S S E E K Q K A A Y I A P S P Y R K I L V L P
R G V G G Y S E L M R A Y E E E L V D S Q R Y G Q P M R
K N L S T S L L E E K L V V Q R F V P F V V Y P N N E P *
H T H Y G V L R E H V A G P K K N S G E F Y T Q K Y F F
R C N S P E P Q E S A R A N P L E Q D I L I E V D L A F
G L D P E A S A N A E E V L G I R M L S R R F R A R A V
H S S A D S A T R A Q N Q W E E L R S N G I R A K S S D
S Q D D H S S V S L E E M S I V H Q Q R K K S Y F V P W
E M I A V P V A L R E V L V A A R E T A A D L N V M K I
S H L P L G P M R Q R L K D E E A L S L A D H F E N K S
P S F L P H E M N E Q K R G E M L I E I N E H P E K E L
E W P G D G S N L V G V E E L H V D D N A W K P R V T V
K A V S P S M R L D M Q G V A G A L Q V F N L K R I L W

Figure 8 (cont.)

14/25






Figure 9

15/25



1 NIK (0.5 mcg)	5 Control	9 NIK + NEMO + IRENΔN
2 NIK (0.5 mcg) + IREN	6 NIK	10 p55
3 NIK + NEMO	7 NIK + IRENΔN	11 p55 + NIK mut
4 NIK + NEMO + IREN	8 NIK + NEMO1-309	12 p55 + NIK mut + IREN



1 IKK-1	5 IKK -1 + NEMO
2 IKK -1 + IREN	6 IKK -1 + NEMO + IREN
3 IKK -1 + NEMO 1-309	7 IKK -1 + NIKmut
4 IKK -1 + IREN + NEMO 1-309	8 IKK -1 + NIKmut + IREN

Figure 10

16/25




Figure 11




Figure 12

18/25

BLAST results of bases 498 – 699 of 10B open reading frame (parts of putative exon 6 of the 10B gene) against htgs databank

>gb|AC007601.3|AC007601 Homo sapiens chromosome 16 clone RP11-276H1, WORKING DRAFT SEQUENCE, 58

unordered pieces
Length = 238514

Score = 398 bits (201), Expect = e-109
Identities = 201/201 (100%)
Strand = Plus / Plus

Query: 1 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
|||||
Sbjct: 128380 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt
128439

Query: 61 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 120
|||||
Sbjct: 128440 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg
128499

Query: 121 ctgaaggagtccacgcaaggagtgcagcctgttcagggagatcacagcctcctctgcc 180
|||||
Sbjct: 128500 ctgaaggagtccacgcaaggagtgcagcctgttcagggagatcacagcctcctctgcc
128559

Query: 181 gtctccatcctcatcaaacct 201
|||||
Sbjct: 128560 gtctccatcctcatcaaacct 128580

>gb|AC034281.2|AC034281 Homo sapiens chromosome 4 clone RP11-65606 map 4, WORKING DRAFT SEQUENCE,

32 unordered pieces
Length = 205309

Score = 398 bits (201), Expect = e-109
Identities = 201/201 (100%)
Strand = Plus / Minus

Query: 1 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
|||||
Sbjct: 119945 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt
119886

Query: 61 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 120
|||||
Sbjct: 119885 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg
119826

Query: 121 ctgaaggagtccacgcaaggagtgcagcctgttcagggagatcacagcctcctctgcc 180
|||||
Sbjct: 119825 ctgaaggagtccacgcaaggagtgcagcctgttcagggagatcacagcctcctctgcc
119766

Figure 13A

19/25

```

Query: 181      gtctccatcctcatcaaacct 201
                |||
Sbjct: 119765 gtctccatcctcatcaaacct 119745

>gb|AC008864.6|AC008864 Homo sapiens chromosome 16 clone CTD-2192M20, WORKING
DRAFT SEQUENCE, 9
    ordered pieces
    Length = 140011

Score = 331 bits (167), Expect = 1e-88
Identities = 193/201 (96%), Gaps = 3/201 (1%)
Strand = Plus / Plus

Query: 1      ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
                |||
Sbjct: 86177 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt 86236

Query: 61      aagtttgctcccaccgtttcagacctcttaaaggagtgcaacgcagaacgtgacctccttg 120
                |||
Sbjct: 86237 aagtttgctcccaccgtttcagacctcttaaaggagtgcaacgcagaatgtga---ccttg 86293

Query: 121     ctgaaggagtgccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
                |||
Sbjct: 86294 ctgaaggagtgccacgcaaggagtgagcagcgtgttcagggagatcacagcctcctctgcc 86353

Query: 181     gtctccatcctcatcaaacct 201
                |||
Sbjct: 86354 atctccatcctcatcaaacct 86374

>gb|AC008740.5|AC008740 Homo sapiens chromosome 16 clone CTD-2547E10, WORKING
DRAFT SEQUENCE, 4
    ordered pieces
    Length = 157848

Score = 331 bits (167), Expect = 1e-88
Identities = 193/201 (96%), Gaps = 3/201 (1%)
Strand = Plus / Plus

Query: 1      ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
                |||
Sbjct: 90259 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt 90318

Query: 61      aagtttgctcccaccgtttcagacctcttaaaggagtgcaacgcagaacgtgacctccttg 120
                |||
Sbjct: 90319 aagtttgctcccaccgtttcagacctcttaaaggagtgcaacgcagaatgtga---ccttg 90375

Query: 121     ctgaaggagtgccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
                |||
Sbjct: 90376 ctgaaggagtgccacgcaaggagtgagcagcgtgttcagggagatcacagcctcctctgcc 90435

Query: 181     gtctccatcctcatcaaacct 201
                |||
Sbjct: 90436 atctccatcctcatcaaacct 90456

```

Figure 13A (cont.)

20/25

>gb|AC025279.2|AC025279 Homo sapiens chromosome 16 clone RP11-231C14, WORKING
DRAFT SEQUENCE, 25

unordered pieces
Length = 183752

Score = 331 bits (167), Expect = 1e-88
Identities = 193/201 (96%), Gaps = 3/201 (1%)
Strand = Plus / Plus

Query: 1 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
|||||
Sbjct: 156098 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt
156157

Query: 61 aagtttgctcccaccggtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 120
|||||
Sbjct: 156158 aagtttgctcccaccggtttcagacctcttaaaggagtcaacgcagaatgtga---ccttg
156214

Query: 121 ctgaaggagtgccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
|||||
Sbjct: 156215 ctgaaggagtgccacgcaaggagtgagcagcgtgttcagggagatcacagcctcctctgcc
156274

Query: 181 gtctccatcctcatcaaacct 201
|||||
Sbjct: 156275 atctccatcctcatcaaacct 156295

>gb|AC023814.3|AC023814 Homo sapiens chromosome 16 clone CTD-2159J19, WORKING
DRAFT SEQUENCE,

19 unordered pieces
Length = 181463

Score = 331 bits (167), Expect = 1e-88
Identities = 193/201 (96%), Gaps = 3/201 (1%)
Strand = Plus / Plus

Query: 1 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
|||||
Sbjct: 55839 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt 55898

Query: 61 aagtttgctcccaccggtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 120
|||||
Sbjct: 55899 aagtttgctcccaccggtttcagacctcttaaaggagtcaacgcagaatgtga---ccttg 55955

Query: 121 ctgaaggagtgccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
|||||
Sbjct: 55956 ctgaaggagtgccacgcaaggagtgagcagcgtgttcagggagatcacagcctcctctgcc 56015

Query: 181 gtctccatcctcatcaaacct 201
|||||
Sbjct: 56016 atctccatcctcatcaaacct 56036

Figure 13A (cont.)

21/25

>gb|AC069176.3|AC069176 Homo sapiens chromosome 11 clone RP11-1122L9 map 11,
WORKING DRAFT

SEQUENCE, 23 unordered pieces
Length = 155414

Score = 331 bits (167), Expect = 1e-88
Identities = 193/201 (96%), Gaps = 3/201 (1%)
Strand = Plus / Minus

Query: 1 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
|||||
Sbjct: 10308 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt 10249

Query: 61 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 120
|||||
Sbjct: 10248 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaatgtgac---cttg 10192

Query: 121 ctgaaggagtcacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
|||||
Sbjct: 10191 ctgaaggagtcacgcaaggagtgagcagcgtgttcagggagatcacagcctcctctgcc 10132

Query: 181 gtctccatcctcatcaaacct 201
|||||
Sbjct: 10131 atctccatcctcatcaaacct 10111

>gb|AC023463.2|AC023463 Homo sapiens chromosome 7 clone RP11-403M2 map 7,
WORKING DRAFT

SEQUENCE, 33 unordered pieces
Length = 178081

Score = 323 bits (163), Expect = 3e-86
Identities = 192/201 (95%), Gaps = 3/201 (1%)
Strand = Plus / Plus

Query: 1 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
|||||
Sbjct: 55935 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt 55994

Query: 61 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 120
|||||
Sbjct: 55995 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaatgtga---acttg 56051

Query: 121 ctgaaggagtcacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
|||||
Sbjct: 56052 ctgaaggagtcacgcaaggagtgagcagcgtgttcagggagatcacagcctcctctgcc 56111

Query: 181 gtctccatcctcatcaaacct 201
|||||
Sbjct: 56112 atctccatcctcatcaaacct 56132

>gb|AC073921.1|AC073921 Homo sapiens chromosome 11 clone RP11-509A19 map 11,
LOW-PASS SEQUENCE

SAMPLING
Length = 60516

Figure 13A (cont.)

22/25

Score = 228 bits (115), Expect = 1e-57
Identities = 143/152 (94%), Gaps = 3/152 (1%)
Strand = Plus / Plus

Query: 50 acgggcagagtaagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacg 109
||||||| |||||||
Sbjct: 59840 acgggcagnataagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaatg 59899

Query: 110 tgacctccttgctgaaggagtccacgcaaggagtgagcagcctgttcagggagatcacag 169
||| || |||||||
Sbjct: 59900 tgaact---tgctgaaggagtccacgcaaggagtgagcagcgtgttcagggagatcacag 59956

Query: 170 cctcctctgccgtctccatcctcatcaaacct 201
||||||| |||||||
Sbjct: 59957 cctcctctgccatctccatcctcatcaaacct 59988

Figure 13A (cont.)

23/25

BLAST results of bases 498 – 699 of 10B open reading frame (parts of putative exon 6 of the 10B gene) against the est databank

```
>gb|AI369689.1|AI369689 qy71g08.x1 NCI_CGAP_Brn25 Homo sapiens cDNA clone
IMAGE:2017502 3'.
      Length = 439

Score = 398 bits (201), Expect = e-109
Identities = 201/201 (100%)
Strand = Plus / Minus

Query: 1  ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
      |||
Sbjct: 276 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 217

Query: 61  aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 120
      |||
Sbjct: 216 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 157

Query: 121 ctgaaggagtccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
      |||
Sbjct: 156 ctgaaggagtccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 97

Query: 181 gtctccatcctcatcaaacct 201
      |||
Sbjct: 96  gtctccatcctcatcaaacct 76

>gb|AW503340.1|AW503340 UI-HF-BN0-akx-f-06-0-UI.r1 NIH_MGC_50 Homo sapiens cDNA
clone
      IMAGE:3078682 5'.
      Length = 520

Score = 331 bits (167), Expect = 6e-89
Identities = 193/201 (96%), Gaps = 3/201 (1%)
Strand = Plus / Plus

Query: 1  ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
      |||
Sbjct: 190 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt 249

Query: 61  aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 120
      |||
Sbjct: 250 aagtttgctcccaccgtttcagacctcttaaaggagtcaacgcagaatgtga---ccttg 306

Query: 121 ctgaaggagtccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
      |||
Sbjct: 307 ctgaaggagtccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 366

Query: 181 gtctccatcctcatcaaacct 201
      |||
Sbjct: 367 atctccatcctcatcaaacct 387
```

Figure 13B

24/25

>gb|AW403206.1|AW403206 UI-HF-BK0-aay-f-08-0-UI.r1 NIH_MGC_36 Homo sapiens cDNA clone

IMAGE:3055622 5'.
Length = 430

Score = 331 bits (167), Expect = 6e-89
Identities = 193/201 (96%), Gaps = 3/201 (1%)
Strand = Plus / Plus

Query: 1 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
|||||
Sbjct: 86 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt 145

Query: 61 aagtttgcctccaccggtttcagacctcttaaaggagtgcaacgcagaacgtgacctccttg 120
|||||
Sbjct: 146 aagtttgcctccaccggtttcagacctcttaaaggagtgcaacgcagaatgtga---ccttg 202

Query: 121 ctgaaggagtgccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
|||||
Sbjct: 203 ctgaaggagtgccacgcaaggagtgagcagcgtgttcagggagatcacagcctcctctgcc 262

Query: 181 gtctccatcctcatcaaacct 201
|||||
Sbjct: 263 atctccatcctcatcaaacct 283

>gb|AW206027.1|AW206027 UI-H-BI1-afy-h-03-0-UI.s1 NCI_CGAP_Sub3 Homo sapiens cDNA clone

IMAGE:2723572 3'.
Length = 332

Score = 331 bits (167), Expect = 6e-89
Identities = 193/201 (96%), Gaps = 3/201 (1%)
Strand = Plus / Minus

Query: 1 ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
|||||
Sbjct: 275 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt 216

Query: 61 aagtttgcctccaccggtttcagacctcttaaaggagtgcaacgcagaacgtgacctccttg 120
|||||
Sbjct: 215 aagtttgcctccaccggtttcagacctcttaaaggagtgcaacgcagaatgtgac---cttg 159

Query: 121 ctgaaggagtgccacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
|||||
Sbjct: 158 ctgaaggagtgccacgcaaggagtgagcagcgtgttcagggagatcacagcctcctctgcc 99

Query: 181 gtctccatcctcatcaaacct 201
|||||
Sbjct: 98 atctccatcctcatcaaacct 78

>gb|AA584128.1|AA584128 no10g11.s1 NCI_CGAP_Phe1 Homo sapiens cDNA clone
IMAGE:1100324 3'

similar to contains element XTR repetitive element ;.
Length = 414

Figure 13B (cont.)

25/25

Score = 331 bits (167), Expect = 6e-89
Identities = 193/201 (96%), Gaps = 3/201 (1%)
Strand = Plus / Minus

```

Query: 1  ggtctgaactccatactctttgcgattaacatcgacaacaaggatttgaacgggcagagt 60
      ||| |||||
Sbjct: 217 ggtccgaactccatactctttgcgattaacattgacaacaaggatttgaacgggcagagt 158

Query: 61  aagtttgctccaccggtttcagacctcttaaaggagtcaacgcagaacgtgacctccttg 120
      |||||
Sbjct: 157 aagtttgctccaccggtttcagacctcttaaaggagtcaacgcagaatgtgac--cttg 101

Query: 121 ctgaaggagtcacgcaaggagtgagcagcctgttcagggagatcacagcctcctctgcc 180
      |||||
Sbjct: 100 ctgaaggagtcacgcaaggagtgagcagcgtgttcagggagatcacagcctcctctgcc 41

Query: 181 gtctccatcctcatcaaacct_201
      |||||
Sbjct: 40  atctccatcctcatcaaacct 20

```

Figure 13B (cont.)

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

IREN PROTEIN, ITS PREPARATION AND USE

the specification of which (check one)

- ☐ is attached hereto;
☐ was filed in the United States under 35 U.S.C. §111 on _____, as
 U.S. Appln. No. _____*; or
☒ was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international
 (PCT) application, PCT/IL00/00517; filed August 31, 2000, entry requested on Monday, March 4, 2002*;
 national stage application received U.S. Appln. No. _____*; §371/§102(e) date
 _____* (* if known)

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below:

Application No.	Country	Filing Date (MM/DD/YYYY)
131719	Israel	09-02-1999

If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing date before that of the earliest application from which foreign priority is claimed (if left blank, then there are none):

Non-Priority Application No.	Country	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional applications listed below:

Application No.	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date (MM/DD/YYYY)	Status (patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with **Customer Number 001444**, which is presently:

BROWDY AND NEIMARK, P.L.L.C.
 624 Ninth Street, N.W.
 Washington, D.C. 20001-5303
 (202) 628-5197

Page 2 of 2 Pages

Atty. Docket: WALLACH=28

Title: IREN PROTEIN, ITS PREPARATION AND USE

U.S. Application filed _____, Serial No. _____

PCT Application filed _____, Serial No. _____

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from SERONO as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR David WALLACH		INVENTOR'S SIGNATURE <i>David Wall</i>	DATE 20/6/02
RESIDENCE Rehovot, Israel <i>TLX</i>		CITIZENSHIP Israel	
POST OFFICE ADDRESS 24 Borochhov St., 76406 Rehovot, Israel			
FULL NAME OF SECOND JOINT INVENTOR Nikolay MALININ		INVENTOR'S SIGNATURE	DATE
RESIDENCE Brookline, Massachusetts USA		CITIZENSHIP Russia	
POST OFFICE ADDRESS 88 Coolidge St., Brookline, Massachusetts 02446 USA			
FULL NAME OF THIRD JOINT INVENTOR Indranil SINHA		INVENTOR'S SIGNATURE	DATE
RESIDENCE Rehovot, Israel		CITIZENSHIP India	
POST OFFICE ADDRESS Weizmann Institute of Science, Beit Kennedy, Room 13, 76100 Rehovot, Israel			
FULL NAME OF FOURTH JOINT INVENTOR Stefan LEU		INVENTOR'S SIGNATURE	DATE
RESIDENCE MASLUL, Israel		CITIZENSHIP Israel	
POST OFFICE ADDRESS Moshav Maslul 7, 85112 Israel			
FULL NAME OF FIFTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

IREN PROTEIN, ITS PREPARATION AND USE

the specification of which (check one)

- [] is attached hereto;
 [] was filed in the United States under 35 U.S.C. §111 on _____, as
 U.S. Appl. No. _____*, or
 [X] was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international
 (PCT) application, PCT/IL00/00517; filed August 31, 2000, entry requested on Monday, March 4, 2002*;
 national stage application received U.S. Appl. No. _____*; §371/§102(e) date
 _____* (* if known)

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below:

Application No.	Country	Filing Date (MM/DD/YYYY)
131719	Israel	09-02-1999

If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing date before that of the earliest application from which foreign priority is claimed (if left blank, then there are none):

Non-Priority Application No.	Country	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional applications listed below:

Application No.	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date (MM/DD/YYYY)	Status (patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with **Customer Number 001444**, which is presently:

BROWDY AND NEIMARK, P.L.L.C.
 624 Ninth Street, N.W.
 Washington, D.C. 20001-5303
 (202) 628-5197

Page 2 of 2 Pages

Atty. Docket: WALLACH=28

Title: IREN PROTEIN, ITS PREPARATION AND USE

U.S. Application filed _____, Serial No. _____

PCT Application filed _____, Serial No. _____

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from SERONO as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR David WALLACH	INVENTOR'S SIGNATURE	DATE
RESIDENCE Rehovot, Israel	CITIZENSHIP Israel	
POST OFFICE ADDRESS 24 Borochihov St., 76406 Rehovot, Israel		
FULL NAME OF SECOND JOINT INVENTOR Nikolay MALININ	INVENTOR'S SIGNATURE <i>[Signature]</i>	DATE 02/29/02
RESIDENCE Brookline, Massachusetts USA <i>MA</i>	CITIZENSHIP Russia	
POST OFFICE ADDRESS 88 Coolidge St., Brookline, Massachusetts 02446 USA		
FULL NAME OF THIRD JOINT INVENTOR Indranil SINHA	INVENTOR'S SIGNATURE	DATE
RESIDENCE Rehovot, Israel	CITIZENSHIP India	
POST OFFICE ADDRESS Weizmann Institute of Science, Beit Kennedy, Room 13, 76100 Rehovot, Israel		
FULL NAME OF FOURTH JOINT INVENTOR Stefan LEU	INVENTOR'S SIGNATURE	DATE
RESIDENCE MASLUL, Israel	CITIZENSHIP Israel	
POST OFFICE ADDRESS Moshav Maslul 7, 85112 Israel		
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

IREN PROTEIN, ITS PREPARATION AND USE

the specification of which (check one)

- [] is attached hereto;
 [] was filed in the United States under 35 U.S.C. §111 on _____, as
 U.S. Appln. No. _____*; or
 [X] was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international
 (PCT) application, PCT/IL00/00517; filed August 31, 2000, entry requested on Monday, March 4, 2002*;
 national stage application received U.S. Appln. No. _____*; §371/§102(e) date
 _____* (* if known)

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below:

Application No.	Country	Filing Date (MM/DD/YYYY)
131719	Israel	09-02-1999

If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing date before that of the earliest application from which foreign priority is claimed (if left blank, then there are none):

Non-Priority Application No.	Country	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional applications listed below:

Application No.	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date (MM/DD/YYYY)	Status (patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C.
 624 Ninth Street, N.W.
 Washington, D.C. 20001-5303
 (202) 628-5197

Page 2 of 2 Pages

Atty. Docket: WALLACH=28


Title: IREN PROTEIN, ITS PREPARATION AND USE

U.S. Application filed _____, Serial No. _____

PCT Application filed _____, Serial No. _____

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from SERONO as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR David WALLACH	INVENTOR'S SIGNATURE	DATE
RESIDENCE Rehovot, Israel	CITIZENSHIP Israel	
POST OFFICE ADDRESS 24 Borochhoh St., 76406 Rehovot, Israel		
FULL NAME OF SECOND JOINT INVENTOR Nikolay MALININ	INVENTOR'S SIGNATURE	DATE
RESIDENCE Brookline, Massachusetts USA	CITIZENSHIP Russia	
POST OFFICE ADDRESS 88 Coolidge St., Brookline, Massachusetts 02446 USA		
FULL NAME OF THIRD JOINT INVENTOR Indranil SINHA	INVENTOR'S SIGNATURE 	DATE 09/07/02
RESIDENCE Rehovot, Israel <i>FLX</i>	CITIZENSHIP India	
POST OFFICE ADDRESS Weizmann Institute of Science, Beit Kennedy, Room 13, 76100 Rehovot, Israel		
FULL NAME OF FOURTH JOINT INVENTOR Stefan LEU	INVENTOR'S SIGNATURE	DATE
RESIDENCE MASLUL, Israel	CITIZENSHIP Israel	
POST OFFICE ADDRESS Moshav Maslul 7, 85112 Israel		
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.

Page 1 of 2 Pages [X] Original [] Substitute [] Supplemental Atty. Docket: WALLACH=28

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

REN PROTEIN, ITS PREPARATION AND USE

the specification of which (check one)

- [] is attached hereto;
 [] was filed in the United States under 35 U.S.C. §111 on _____, as
 U.S. Appln. No. _____*; or
 [X] was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international
 (PCT) application, PCT/IL00/00517; filed August 31, 2000, entry requested on Monday, March 4, 2002*;
 national stage application received U.S. Appln. No. _____*; §371/§102(e) date
 _____* (* if known)

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below:

Application No.	Country	Filing Date (MM/DD/YYYY)
131719	Israel	09-02-1999

If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing date before that of the earliest application from which foreign priority is claimed (if left blank, then there are none):

Non-Priority Application No.	Country	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional applications listed below:

Application No.	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date (MM/DD/YYYY)	Status (patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C.
 624 Ninth Street, N.W.
 Washington, D.C. 20001-5303
 (202) 628-5197

Page 2 of 2 Pages

Atty. Docket: WALLACH=28

Title: IREN PROTEIN, ITS PREPARATION AND USE

U.S. Application filed _____, Serial No. _____

PCT Application filed _____, Serial No. _____

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from SERONO as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR David WALLACH	INVENTOR'S SIGNATURE	DATE
RESIDENCE Rehovot, Israel	CITIZENSHIP Israel	
POST OFFICE ADDRESS 24 Borochhov St., 76406 Rehovot, Israel		
FULL NAME OF SECOND JOINT INVENTOR Nikolay MALININ	INVENTOR'S SIGNATURE	DATE
RESIDENCE Brookline, Massachusetts USA	CITIZENSHIP Russia	
POST OFFICE ADDRESS 88 Coolidge St., Brookline, Massachusetts 02446 USA		
FULL NAME OF THIRD JOINT INVENTOR Indranil SINHA	INVENTOR'S SIGNATURE	DATE
RESIDENCE Rehovot, Israel	CITIZENSHIP India	
POST OFFICE ADDRESS Weizmann Institute of Science, Beit Kennedy, Room 13, 76100 Rehovot, Israel		
FULL NAME OF FOURTH JOINT INVENTOR Stefan LEU	INVENTOR'S SIGNATURE <i>[Signature]</i>	DATE 10.7.2002
RESIDENCE MASLUL, Israel ILX	CITIZENSHIP Israel	
POST OFFICE ADDRESS Moshav Maslul 7, 85112 Israel		
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.